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ABSTRACT
BIOANALYTICAL APPLICATIONS OF PROTEIN-LIGAND INTERACTIONS
Kaitlynn R. Davenport, PhD.
Department of Chemistry and Biochemistry
Northern Illinois University, 2016
Dr. Oliver Hofstetter, Director.
Biorecognition is the ability of biological macromolecules, particularly proteins, to
interact and form specific complexes with other macromolecules or small molecules, called
ligands. Complementarity of the ligand to the binding site of the macromolecule with regard to
both shape and electrostatic interactions increases the chances of the interaction to occur and
stabilizes the resulting complex. The high specificity and affinity frequently observed with
protein-ligand interactions has found wide application in fields such as biotechnology and
medicine ranging from affinity separations to drug screening.
In this work, specific protein-ligand interactions were exploited for two conceptually
different types of applications. The first part of this dissertation describes the use of an antimethotrexate single domain antibody for the separation of aminopterin, folate and methotrexate
by immunoaffinity chromatography. In particular, the effect of random versus site-directed
immobilization techniques on the performance of antibody-based HPLC columns was
investigated. Genetic engineering techniques were utilized to modify the C-terminus of the
antibody in order to facilitate its oriented coupling to a chromatographic support material and,
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thus, optimize the binding capacity of resulting columns. Frontal analysis was employed to
compare two site-directed approaches with random antibody coupling.
The second part reports the utilization of biorecognition to target specific compounds in
latent fingermarks. Since fingerprints are unique to an individual and do not change over time,
they are considered to be the most important piece of physical evidence in criminal
investigations. Here, three different types of biorecognition reagents, namely classically raised
polyclonal antibodies, recombinantly expressed VHH antibodies, and lectins, were evaluated for
their utility to visualize latent fingermarks based on their interactions with components contained
in marks. Furthermore, a number of fusion proteins of VHHs and various fluorescent proteins
were produced to allow for “direct” fingermark detection, i.e., visualization without the need of
chemical labeling or additional visualization steps.
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CHAPTER I:
INTRODUCTION
Biorecognition is the ability of biological macromolecules (receptors), in particular
proteins, to interact and form complexes with other macromolecules or small molecules, called
ligands.1 The recognition occurs through a variety of different forces, with both steric and
electronic characteristics of the receptor governing the ligands that can be accepted within its
binding site. Examples of physico-chemical forces involved include Lifschitz-van der Waal’s
forces, dipole-dipole and hydrogen bonding. Increased complementarity in both shape and
electronic characteristics between the binding site of the receptor and the ligand will increase the
chances of the interaction occurring and result in a more stable complex. Receptor-ligand
interactions are the basis for life since, e.g., a cell’s ability to respond and react to both external
and internal stimuli is based on cascades of such complexes, which are of crucial importance for
its survival.2
Protein-ligand interactions are reversible, non-covalent reactions that can be expressed as
shown in equation 1:

Eq 1.1

2

The association step is governed by the on rate, kon , while the dissociation of the complex is
related to koff. 3 The strength of the assembly of the complex can be expressed as the ratio of the
concentrations of products over the reactants, or the ratio of rate constants, and is denoted Ka, the
association constant:
Ka =

[RL]

𝑘

= 𝑘 𝑜𝑛
[R][L]

𝑜𝑓𝑓

Eq 1.2

Association constants, while describing the strength of interaction, also give some information
on the lifetime of a complex. For example, enzyme-substrate reactions have Kas that typically
range from 103-106 M-1. Assuming that the reactions are diffusion-controlled, with rates of 1091010 M-1 s-1, the complexes are only stable for μsec to msec.3-4 Antibody-antigen interactions,
generally, have association constants from 106-1011 M-1, representing lifetimes on the order of
seconds to hours. Due to the diverse types of cellular processes to occur, the wide range of
affinities and lifetimes are essential.3 The strength, or affinity of the interaction, is more
commonly described as Kd, which is the inverse of Ka, and expressed in molar units. While there
are no consistent guidelines regarding ranges of affinity, the often used terms “low”, “medium”
and “high affinity” may be reasonably associated with Kds of about 10-3-10-6 M, 10-6 -10-9 M, and
10-9 or lower, respectively.
Protein-ligand interactions are not only characterized by affinity, but also specificity.
Specificity can be defined as the ability of a receptor’s binding site to interact with a particular
ligand, but to exclude other, possibly closely related structures. Thus, the larger the number of
ligands a receptor accepts, the less specific it would be. While higher affinities often seem to be
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related to the involvement of non-polar interactions, polar and electrostatic interactions appear to
have a strong influence on specificity.5
Antibody-antigen interactions represent a particularly well-studied protein-ligand system.
In vertebrates, antibodies are produced to and help eliminate foreign materials that have invaded
the organism. When, e.g., a foreign protein is encountered by a B-lymphocyte, which possesses
membrane-bound antibodies, the foreign material is internalized, digested, and presented on the
cell-surface in complex with MHC II proteins. Specific interactions with helper T cells result in a
stimulation, proliferation, and differentiation into plasma cells, which produce and secrete a
soluble form of the antibody that can bind to the foreign protein and mark it for elimination by
other components of the immune system such as phagocytes.
Though there are several classes of antibodies, or immunoglobulins (Ig), the most abundant
present in serum is immunoglobulin G (IgG).6 The molecule is comprised of four polypeptide
chains - two heavy chains and two light chains - that combine to form a Y-shaped structure as
seen in Figure 1. The entire Y structure is held together by inter-chain disulfide bonds between
the two heavy chains, as well as disulfide bonds between the heavy and light chains on each side
of the overall symmetric molecule. The heavy chains differ between the classes, denoted by α
(IgA), γ (IgG), δ (IgD), ε (IgE), and μ (IgM).6 Two light chain isotypes are possible - λ and κ and can be combined with any of the heavy chains.7 Though the molecular weight of an IgG is
approximately 150 kDa, interaction with antigens only occurs via regions within the variable
domains, the so-called complementarity-determining regions (CDRs). Hypervariability within
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the CDRs based on gene recombination and mutations yields an enormous diversity of antibodies
in vertebrates, allowing for the production of an estimated 1011 potential different binding sites.

Figure 1.1: Schematic of an Immunoglobulin Class G. Domains labeled as CH are constant domains within the
heavy chain, while CL represents the constant domain within the light chains. VH and VL are the antigen-binding
variable domains within the heavy and light chains, respectively8. The heavy and light chains are held together by
disulfide bonds in the constant regions. The hinge region is also connected by disulfide bonds. Adapted from
Reference 5.

While it is theoretically possible to raise an antibody against any antigen, it has been
found that low molecular weight molecules on their own tend to not illicit an immune response.
However, as demonstrated by Karl Landsteiner almost one hundred years ago, antibodies can be
raised against such “haptens,” if they are conjugated to a protein carrier, and the resulting
immunogens injected into an animal.9
Since the immune response to a foreign molecule will create a variety of different
antibodies with different specificities, each of which being produced by a different cell clone, the
serum obtained from an immunized animal, such as rabbit, chicken, sheep, or mouse,10 is
referred to as a polyclonal antibody serum. The desired antibody fraction can be isolated from

5

either the serum or interstitial fluid of the immunized animal. Rabbits are used the most
frequently due to their manageable size, ease of serum collection, and the fact that they only have
one IgG class.10 Polyclonal production has limitations, such as batch variation and a limited
lifespan of the animal, which leads to issues in reproducibility.11 In 1975, Kohler and Milstein,
however, developed the hybridoma technology to create monoclonal antibodies.12 The fusion of
a mouse myeloma cell and a mouse spleen cell can create an immortalized cell line that secretes
antibodies of the exact same specificity. Thus, monoclonal antibodies with desired characteristics
can be selected for during the screening process, and an immortal cell line can be created, frozen
and re-cultivated as needed.
As the use of antibodies becomes more prominent in biotechnology, large scale
production as well as optimization of antibody properties may be desired. For example, full-sized
IgGs have difficulties penetrating certain tissues and may have long clearance times, which can
be disadvantageous depending on the application.13 Several antibody fragments, on the other
hand, can retain the binding affinity of the antibody for its antigen, while allowing utilizations
unattainable with the parent molecule. For example, by using a smaller fragment, such as a
single-chain variable fragment (ScFv), the plasma half-life is reduced from weeks to only 0.5-2
hours. Using a Fab decreases the plasma clearance time to 14-15.5 hours.13 Furthermore,
expression of antibody-fragments using bacterial expression systems is significantly easier and
less extensive than cultivating monoclonal antibodies.
Another type of antibodies that offers similar potential advantages over classically
produced IgGs are heavy-chain only antibodies. In 1993, Hamers-Casterman et al. discovered
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such antibodies, which do not have light chains, in camelids.14 A representative structure is
displayed in Figure 1.2. These single domain antibodies (sdAb), or Nanobodies® are found in
both sharks and camels, and possess two binding sites that are composed of regions within only
the heavy chains.13, 15 These antigen-recognition regions are each formed by a single protein
domain containing the three complementarity determining regions (CDRs), which is in contrast
to traditional IgGs that have two protein domains - one from the heavy chain and one from the
light chain - that contribute a total of six CDRs.15 Interestingly, the VH domain of human
antibodies share 80% sequence similarity to the variable domains of camelid antibodies
(VHH).16 The small size of VHHs makes them better candidates for recombinant expression and
results in faster clearance rates in vivo.17 Consequently, VHHs have become popular as, e.g.,
diagnostics,18 crystallization chaperones,19 and therapeutic reagents.20

Figure 1.2: Schematic of a Heavy-Chain Only Antibody from Camels. Though it is structurally similar to the IgG by
maintaining the Y shape, it only contains two heavy chains. Only one domain in each chain, the variable region
(VHH), confers the binding specificity of the antibody.

7

Antibodies and their fragments have found numerous applications as capture reagents,
with affinity chromatography being one of the oldest. The general concept of this technique (see
Fig. 1.3), which exploits the specific interactions between two binding partners in order to
separate one or the other from a crude mixture, was first described by Cuatracasas, Wilchek, and
Anfinsen in 1968.21 Over the years, affinity chromatography has found numerous applications
using not only antibody-antigen interactions (known as immunoaffinity chromatography, or
IAC), but also, e.g., lectin-carbohydrate, enzyme-substrate, and receptor-hormone interactions.
Lectin-affinity chromatography, for example, is nowadays frequently utilized in proteomics to
isolate glycoproteins.22 A chromatographic method related to classical affinity chromatography
is Immobilized Metal Affinity Chromatography (IMAC), which utilizes the complexation
between solid-phase immobilized nickel and cobalt ions and hexahistidine tails for the
purification of appropriately modified peptides or proteins.23
A special application of affinity chromatography, known as frontal affinity
chromatography (FAC), can be used to determine the Kds and number of available binding sites
(Bt) of a protein immobilized in an affinity column.24 This is advantageous for a variety of
applications such as the determination of drug-protein interactions. A schematic of FAC is
shown in Figure 1.4 In FAC, ligand at a known concentration ([A]0) is flowed over the column in
order to saturate the binding sites available on the receptor-derivatized support material. Once
saturation is achieved, excess ligand can no longer bind to the column and elutes. Eventually, the
elution profile, called the breakthrough curve, will plateau.
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Figure 1.3: Schematic of an Affinity Chromatography System. A complex sample, represented by differently
colored shapes, is applied to a column, which contains an immobilized binding partner specific to one of the
compounds. A crude sample is applied to the column initially. a) Application of optimal binding buffer for the
interaction of the two binding partners (yellow and green) allows the elution of the non-binders in the flow through.
b). Washing with the binding buffer minimizes non-specific interactions by non-binders, allowing only the two
binding partners to remain. c). Application of an elution buffer disrupts the interaction between the binding partner,
eluting the components that interact with the immobilized binding partner on the stationary phase.
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Figure 1.4: Fontal Affinity Chromatography. A constant concentration of ligand is flowed over an affinity column.
Eventually, all of the binding sites will be saturated (a) with compound, which will lead to ligand elution (b). Ligand
will be detected, yielding a sigmoidal breakthrough curve.

1
[A]0 ×(V−V0 )

K

1

Bt

[A]0

= ( d) × (

)−

1
Bt

Eq. 1.3

To determine the number of binding sites as well as the Kd, several injections with
varying ligand concentrations are performed, and the half value of the plateau is first determined
and used to obtain the so-called elution volume (V). The difference between the void volume
(Vo), obtained with a compound that does not interact with the receptor, and the elution volume
yields the retardation volume (V-Vo) of the ligand at each concentration. The inverse of the
initial concentration is then plotted versus the inverse of the initial concentration multiplied by
the retardation volume. Using the frontal analysis equation, equation 1.3, a linear double
reciprocal Lineweaver-Burke type plot is created, seen in figure 1.5. Frontal analysis has found
applications not only for characterizing solid-phase immobilized receptors, but also for, e.g.,
screening for drug targets25 and fragment hits.26
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Figure 1.5: Schematic of a FAC Plot. Plotting of 1/A0 vs. 1/[A0 (V-V0)] yields a line that allows for determination of
the number of active binding sites and Kd by determining the inverse of the Y intercept and the negative inverse of
the X intercept, respectively.

A more recent application of antibodies as capture reagents is in Forensic Science for the
visualization of latent fingermarks.27 Fingerprints have been used for identification purposes
since 300 BC, but they have only been employed in criminal investigations since the 1900s.28
Fingermarks are considered one of the strongest physical evidence used in court.29 The ability to
employ fingermarks as evidence is based on the fact that fingerprints are unique to an individual
and do not change over time.30 Therefore, marks left at a crime scene can be connected to an
individual and may lead to the identification of persons of interest.
There are three types of marks that can be left at a crime scene - visible (patent),
impression (plastic), and latent (invisible) prints. 28 A plastic print is a three-dimensional print
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retained in a substance like clay, candle wax, or putty.28, 31 A patent print contains colored
material deposited with the print, such as paint, or is the result of materials removed from a
surface, such as dust.31 These marks can usually be enhanced by optical methods, e.g., with
special light sources, filters and lenses without the need for surface-altering materials such as
powders.32 Since latent marks, on the other hand, are invisible to the naked eye, special methods
are required for visualization and detail enhancement, respectively. The quality of a print is
based on the level of detail that can be observed. Level one details ridge characteristics and flow,
such as loops and whirls.33 Level two describes individual ridge attributes, such as bifurcations
and terminations.33 Level three details include the morphology of the ridge, such as pore
locations and texture of the ridge.33 As the level increases, the amount of detail and information
obtained increases. 33
The most common development techniques can be divided into two different categories:
physical methods such as powder dusting, iodine and cyanoacrylate fuming, and chemical
methods, e.g., ninhydrin spraying and silver nitrate soaking.28 Physical methods rely on the nonspecific attachment or adsorption of a substance to the mark, while chemical methods involve a
specific chemical reaction with the print.28 Dusting with powder is the most common and
simplest approach to developing fingermarks.31 Powders of various colors and particle sizes can
be utilized to create a visible print. Ninhydrin reacts with amino acids to create a purple complex
and can be applied by spraying or dipping the mark into a ninhydrin-containing solution.28, 31
However, the solvents used to dissolve ninhydrin can damage the substrate, i.e., the material the
mark is deposited on, which can be detrimental.31 Iodine fumes physically adsorb to the
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fingermark, while cyanoacrylate fumes polymerize in the presence of a nucleophile.28 Silver
nitrate is used to react with the chloride ions present in sweat, which creates a silver chloride
precipitate.
The selection of the development method depends on the substrate as well as the age of
the mark. Considering that 98-99% of the deposited material is aqueous, the effectiveness of
physical methods - such as powder dusting - is limited depending on the age of the mark,
whereas ninhydrin spraying has been effective on marks as old as 30 years.29 Substrates can be
characterized as smooth, rough, porous or non-porous. These surface attributes have a strong
influence on the type of technique that can be used to develop the mark.
There are three different types of glands that secrete onto the surface of the skin apocrine, eccrine and sebaceous glands.28 Apocrine glands are the least studied and exist in the
axillary, perineal, and inguinal area.28 However, it is currently not known what components of
fingermarks originate from apocrine glands.34 Sebaceous glands are most concentrated on the
scalp and the face, and are typically associated with hair follicles. Sebaceous glands typically
empty hydrophobic components, such as wax esters, fatty acids and a variety of different lipids.28
Eccrine glands are the most abundant on the palms of the hands and the soles of the feet. Eccrine
secretions predominantly consist of water, inorganic ions, and small organic molecules like
pyruvate as well as proteins.28
The occurrence of a wide variety of biomolecules in fingermarks, as well as the ability to
tailor-make antibodies makes immunolabeling an attractive technique for enhancement of latent
fingermarks. The first report on employing immunolabeling for fingermark visualization utilized
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antibodies against different blood type antigens.35 In addition, fingermarks were developed by
successfully targeting protein components such as human serum albumin, dermacidin, cathepsin,
and keratin. 36 Furthermore, antibodies raised against metabolites of illicit substances were used
to gather additional information about the donor, in particular, whether they used nicotine,
morphine, cocaine, or cannabis. 36
Since the mere interaction between an antibody and a corresponding target deposited with
a fingermark will not by itself allow visualization, appropriate labels such as fluorophores must
be introduced. Typically, fluorophores are highly conjugated aromatic compounds, which
possess electrons that can be excited to a higher energy level. To return to the ground state, the
electron must release energy, which can occur in a variety of ways, one of which is fluorescence.
While light energy of a particular intensity, i.e., wavelength, is required to lift electrons to a
higher level (hence, the term “excitation wavelength”), their return to the ground state also
releases a distinct amount of energy and occurs at the “emission wavelength.”37 The difference
between the excitation and emission maximum is called the Stokes shift.38 The efficiency of
fluorescence can be calculated as the quantum yield by dividing the number of fluorescing
photons by the photons absorbed.37 Another parameter used to characterize fluorescence is the
“brightness,” which can be calculated by multiplying the molar absorptivity at the excitation
wavelength by the quantum yield.38
There are a variety of different fluorophores that can be introduced into biological systems
for detection and tracking purposes.39 Small molecule organic probes are usually highly
conjugated substances structurally related to fluorescein, rhodamine, Cy5, and BODIPY dyes.39-40
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Altering substituents bound to the core rings changes the optical properties of the fluorophore,
which allows for tailoring of the fluorescent probes to have the desired characteristics. Many of
these fluorophores have chemically reactive derivatives to allow labelling of, e.g., proteins.39
More recently, small fluorescent nanoparticles called quantum dots have been used in biological
systems. The optical properties of quantum dots (QDs) are dependent on the composition of the
nanoparticle, its size and surface modifications, but, generally, their emission wavelength has a
narrow Gaussian distribution.41 The most commonly used QDs are created from Cadmium
Tellurium (CdTe) or Cadmium Selenium (CdSe). Quantum dots can be introduced into a
biological system in a variety of different methods; i.e., electrostatic interactions, or the surface
capping of the QD with reactive ligands for binding to the molecule. 41
Another type of fluorescent markers utilized in biological detection are fluorescent
proteins, which were originally discovered in jellyfish and light-harvesting coral. Following the
discovery of the first fluorescent protein, GFP, researchers introduced a variety of different
mutations that resulted in the production of variants of different color, and the availability of a
fluorescent protein “color pallet.” The variants include blue, green and yellow proteins which
possess different excitation maximums, extinction coefficients and fluorescent properties.42 Also
other characteristics of the wild-type GFP were enhanced, e.g., with regard to the number of
excitation peaks, stability of folding at elevated temperatures, and codon utilization for
mammalian expression.43 This allowed for introduction of fluorescent proteins as a “fusion
protein,” where the fluorescent protein is used as an in vivo reporter for, e.g., folding,44
expression,45 and biosensing such as FRET applications.46 It was, furthermore, discovered that
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also reef corals and anemones contain fluorescent proteins, which were utilized to further expand
the color pallet to shades of red and orange.42 By now, an expansive library of fluorescent
proteins is available to choose from, depending on the necessities and limitations of the
application. 47
This dissertation is comprised of two parts, each of which reports the utilization of
receptor proteins for a bioanalytical application.
The first describes the use of an anti-methotrexate VHH for the separation of
aminopterin, folate and methotrexate by immunoaffinity chromatography. In particular, the
effect of random versus site-directed immobilization techniques on the performance of antibodybased HPLC columns was investigated. Genetic modifications were made at the C-terminus of
the VHH to facilitate its oriented coupling to the support material in order optimize the binding
capacity of the resulting columns. Frontal analysis was then employed to assess which sitedirected coupling technique increases the binding capacity the most.
The second part reports the utilization of biorecognition to target specific compounds in
latent fingermarks. Three different types of biorecognition reagents were evaluated for their
ability to target specific compounds in latent fingermarks: classically raised polyclonal
antibodies from rabbits, recombinantly produced VHH antibodies, and lectins. Furthermore, a
number of fusion proteins of VHHs and various fluorescent proteins were produced to allow for
“direct” fingermark detection, i.e., visualization without the need of chemical labeling or
additional visualization steps.

16

CHAPTER II
MATERIALS AND METHODS

1: Description of Chapter Layout
This chapter covers the wide variety of experimental techniques that were used in this
dissertation. Molecular biology methods include, e.g., protein expression and purification as well
as overlap extension mutagenesis by PCR. Also, a number of classical immunological
approaches are presented such as the synthesis of haptens and immunogens, immunization in
order to raise polyclonal antibodies, testing of immune responses, and purification of antibodies.
Ligand binding techniques described include isothermal titration calorimetry and enzyme-linked
immunosorbent assay (ELISA). Furthermore, descriptions for the activation and derivatization of
support materials and packing of high performance immunoaffinity columns are given, and
procedures relating to frontal affinity chromatography (FAC) and method validation of HPLC
columns are presented. Results and a more specific discussion of techniques can be found in
relevant subsequent chapters.
2: Materials
All solutions were prepared using water purified in a Milli-Q Millipore system
(Millipore, Darmstadt, Germany). Disuccinimidyl carbonate (DSC) and 4dimethylaminopyridine (DMAP) were purchased from Nova Biochem®(Waltham, MA). Goat
anti-rabbit antibody and Streptavidin - both labeled with Horseradish peroxidase (HRP) - were
purchased from Jackson ImmunoReseach Inc (West Grove, PA). Promega (Madison, WI)
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provided the Wizard® miniprep kits, PCR clean up kits, dinucleotide triphosphates (dNTPs), 6x
DNA gel loading buffer, and DNA ladders (1 kbp and 100 bp, respectively). Applied Biosystems
(Cambridge, MA) supplied the 20 μm POROS-OH. NeutrAvidin, Nunc Maxisorp ® ELISA
plates, keyhole limpet hemocyanin (KLH), DpnI restriction enzyme and Phusion polymerase kit
(containing enzyme buffers and 100 % DMSO ) were provided by Thermo Fisher Scientific
(Waltham, MA). Teknova (Hollister, CA) provided isopropyl-β-D-galactoside (IPTG).
Cholesterol ester and imidazole were purchased from Acros (Geel, Belgium). Sigma-Aldrich (St.
Louis, MO) supplied the designed primers, Atto 610 NHS, Complete and Incomplete Freund’s
Adjuvant, respectively, citric acid, dicyclohexyl carbodiimide (DCC), deoxycholic acid,
cholesterol, RNase A from bovine pancreas, caffeine, hemin, cholic acid, HyCasein, gelatin,
bovine serum albumin (BSA), Tween 20, guanidine, glutathione (reduced and oxidized), εaminocaproic acid, spectinomycin, arabinose, tris(hydroxymethyl)aminomethane, Sepharose™
ClB4, o-phenylenediamine (OPD), biotin, sodium azide, 1,6-diamino hexane, and 3,3’,5,5’tetramethylbenzidine (TMB). 30% hydrogen peroxide, sodium chloride, sodium phosphate
monobasic, sodium phosphate dibasic, potassium phosphate, ammonium hydroxide, hydrochloric
acid, sulfuric acid, acetic acid, methanol, carbencillin, ampicillin, glass slides and agarose were
provided by Fisher Inc (Waltham, MA). Cell lines XL1blue, TOP10 and BL21DE3 were
purchased from Strategene (LaJolla, CA). Adenosine 5’-triphosphate (ATP), Lysogeny Broth
(LB), and LB agar were provided by Fisher Bioreagents (Rockville, MD). Nitrocellulose was
obtained from Maine Manufacturing, LLC (Stanford, ME).
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3: Instrumentation
Protein purifications were performed on one of three FPLCs: a BioRad biologic LP
(Hercules, CA), a BioRad Biologic Duoflow (Hercules, CA), or an Akta PrimePlus (GE,
Fairfield, CT). End-over-end rotations of samples were performed on a Barnstead Thermolyne
Labquake (BD, Franklin Lake, NJ). Spectrophotometric data was determined using a Nanodrop
ND-1000 from Thermo-Fischer (Waltham, MA). Samples were centrifuged in a Beckman
coulter Avanti J-E centrifuge, or a Beckman coulter GS-6R table top centrifuge (Brea, CA).
Microcentrifuge tube centrifugations were performed in an Eppendorf (Hamburg, Germany)
centrifuge model 5415C. Cultures were shaken in the New Brunswick Scientific Excella
incubator shaker series - the E24 incubator for overnight and sub-cultures, and the E25 for the
large cultures (Enfield, CT). Polymerase Chain Reactions (PCRs) were performed on the BioRad
ICycler (Hercules, CA). All isothermal titration calorimetry (ITC) experiments were performed
on the Microcal VP ITC microcalorimeter (Northampton, MA), and all samples were degassed
using a Microcal thermovac (Northampton, MA). Columns were packed with an Alltech Slurry
Packer Model 1666 (Deerfield, IL). A Hitachi HPLC system, consisting of an L7100 pump with
degasser, an L-4000 UV detector and a Rheyodyne injector with a 20 μL stainless steel loop, was
used for the HPLC and frontal affinity chromatography investigations (Hitachi, Naperville, IL).
ELISA plate readings were taken on a FLUOstar galaxy containing BMG evaluation software
(Hamburg, Germany). Fluorescence microscopy images were taking with a Nikon Eclipse E-600
Research Light Microscope with a 0.6x objective. Images were captured using a Nikon-Fi1c
digital camera system with Nikon NIS-Elements image capture and optimization software
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(Melville, NY). GFP images were captured with an Endow GFP bandpass emission filter set (Ex:
450-490 nm, Em: 500-550 nm) (Melville, NY). The mRuby images were captured with a TRITC
HYQ filter set (Ex: 530-560 nm, Em: 590-650 nm) (Melville, NY).
Fingerprint images that were not obtained on the epifluorescence microscope were
obtained at the University of Technology Sydney (UTS) with a Poliview system provided by
Rofin Forensic (Dingley Village, Melbourne, Australia). The Poliview system contains a Rofin
PL550XL forensic light source, which uses a xenon arc lamp as the broadband light source
(Dingley Village, Melbourne, Australia). A bandpass barrier camera filter and a 60 mm Nikon
macro lense is equipped to a Peltier-Cooled CCD camera (Dingley Village, Melbourne,
Australia). Excitation and emission wavelengths used for fluorescein, TSapphire, and mAmetrine
were 450±45 nm, and 530±20 nm. Atto 610 and mRuby fusions were excited at 590±27.5 nm
and emission was either 650±20 nm or 700±20 nm.
4: Molecular Biology Techniques
4.1: Overlap Extension Mutagenesis
Overlap Extension mutagenesis (OEM) is a two-PCR-step protocol that involves the
creation of mega primers for gene insertion without the use of restriction enzymes or ligases.48
Here, OEM was utilized to create fusion proteins between a target protein (e.g., anti-caffeine
VHH) and a fluorescent protein. Table 2.1 contains the primers utilized to create these fusion
proteins.
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Table 2.1: Primers Designed for the First OEM PCR. The primers are chimeric- the 3’ ends of the forward and
reverse primers are complementary to the VHH, while the 5’ are complementary to the fluorescent protein. 49

Gene inserted
GFP

mRuby
mAmetrine/
TSapphire

Forward Primer
5’- CACCCAAGTAACCGTAAGCAG
CGGTGGTATGAGTAAAGGAGAA
GAACTTTTCACTGG-3'
5’-ACCCAAGTAACCGTAAGCAGC
GGTGGTGTGGTAGCGGTATGGCT
AGCATGACTGGT-3’
5’-ACCCAAGTAACCGTAAGCAGC
GGTGGTGTGGTAGCGGTATGGCT
AGCATGACTGGT-3’

Reverse Primer
5’-GGTGGTGGTGGTGGTGCTC
GAGCTATTATTTGTATAGTTC
ATCCATGCCATGTGTAATC-3’
5’-CACCCAAGTAACCGTAAGC
AGCGGTATGGCTAGCATGACT
GGT-3’
5’-TTACTTGTACAGCTCGTCC
ATGCTGGTGGTGGTGCTCGAG
CTA-3’

All primers were designed to have the same annealing temperature with their corresponding
parent DNA, which was between 65-70°C. The fluorescent protein DNA was used as the
template for the first PCR reaction and was isolated using the Wizard® Plus SV Miniprep DNA
purification system following the manufacturer’s protocol.50 Then, the reagents in Table 2.2 were
mixed in a 250 μL thin-walled PCR tube. Once combined, the reaction mixture was spun down
for a maximum of 30 seconds. Then, 1U of Phusion polymerase was added. The thermocycler
was set to the settings in Table 2.3.
Following the completion of the PCR cycles, the DNA was purified in a 1.4% (w/v)
agarose gel. The entirety of the PCR reaction was mixed with 6x gel loading buffer, and 30 μL
of the sample were placed in each well; a 100 bp DNA ladder was included for comparison.
Separation of the bands was performed at 200 V for 1 hour. Then, the gel was stained for 30
minutes in ethidium bromide and visualized at 365 nm. Positive bands were excised from the gel,
and DNA was purified from gel slices using the PCR/Gel clean up kits from Promega following
the manufacturer’s instructions.51
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Table 2.2: Reagents Added to the PCR Reaction to Create the Megaprimers for Creation of the Fluorescent Protein
Fusion. The parent DNA contains the gene to be isolated in the megaprimer. The forward and reverse primers will
anneal to the parent DNA, but also contain overhangs to anneal to the parent vector. The polymerase has the lowest
error rate in the HF buffer and DMSO decreases the secondary structure of the primers. Deoxynucleotide
triphosphates (dNTPs) are used by the polymerase to extend the DNA strand.

Name
Parent DNA
Forward and Reverse Primers
dNTPs
100% DMSO
10 x HF buffer
Nuclease Free Water

Amount
250 ng total
500 ng of each primer
1 μL of 10 mM dNTP mix
1.5 μL
5 μL
To 49.5 μL

Table 2.3: Thermocycler Settings for OEM PCR #1. The optimal annealing temperature was determined in an initial
test PCR using various annealing temperatures while maintaining all other steps. This annealing temperature was
utilized in subsequent PCRs using the same insert DNA.

Initial Melt
PCR Cycling
Total Cycles - 35
Final elongation

95 °C for 1 minute
95°C for 1 minute
50-60°C for 1 minute
68°C for 90 seconds/kb of elongation
68°C for 10 minutes

The second PCR utilized the VHH DNA as the template DNA and the isolated DNA
from the first PCR as the primers for the reaction. The two separate DNA fragments come
together to create the fusion protein’s gene as shown in Figure 2.1. The second PCR is performed
with the components listed in Table 2.4 combined in a thin-wall PCR tube. The second PCR was
performed as described in Table 2.3, however fewer cycles were used (25 rather than 35).
Following the completion of the PCR reaction, methylated parent DNA was digested by
adding 10 U of DpnI restriction enzyme for 1 hour at 37 °C. DNA was transformed into XL1Blue cells by heat shocking 2-5 μL of DNA into 40 μL of competent XL1-blue cells. The cells
and DNA were incubated on ice for 30 minutes, followed by 45 seconds in a 42°C water bath.
Then, the mixture was put on ice again for 2 minutes and incubated with 300 μL of super-
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optimal broth with catabolite suppression (SOC media) for 60 minutes at 37°C. Next, the culture
was plated on LB agar plates containing antibiotics and incubated at 37°C overnight. Positive
colonies were stored at 4°C and the gene insertion was confirmed by DNA sequencing.

PCR #2

Figure 2.1: Depiction of the Second OEM PCR to Create the Fused Gene. The vector containing the accepting gene
(gene 2, blue) is mixed with 10-250x molar excess of the insert (gene 1, green). Due to the associated overlaps built
into gene 1 in the first PCR, the polymerase will amplify the entire gene as one, rather than two fragments. This
results in the two genes fused together, without the use of ligases or restriction enzymes.

Table 2.4: Reagents Added to the Second PCR Reaction to Create the Genetic Fusion. Gene 1 was amplified and
purified from the previous PCR reaction with overhangs that anneal to the parent vector (gene 2). The other
components were the same as in the previous reaction, but adjusted for the 25 μL volume.

Name
Parent Vector (Gene 2)
Gene 1 (megaprimer)
dNTPs
100% DMSO
10 x HF buffer
Nuclease Free Water

Amount
10-100 ng
50-250 molar excess over Gene 2
0.5 μL of 10 mM dNTP mix
1.5 μL
2.5 μL
To 24.5 μL

4.2: Protein Expression and Purification
The expression of recombinant proteins depends on the plasmid vector that the
recombinant protein DNA is in and, thus, the type of cells that are used. Table 2.5 shows the
recombinant proteins utilized in this dissertation, their corresponding vector, cell type utilized for
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expression, and the location the protein was found in following cell lysis. All of the vectors,
except the ones for αRNAseA-fluorescent proteins, contained genes for ampicillin resistance
following the protein sequences. The cells expressing the αRNaseA-FP fusion also contained a
second plasmid - pBB550 - which included the molecular chaperones to increase the amount of
soluble protein expressed. In order to select for both plasmids, ampicillin was used to select for
the αRNaseA FP, and spectromycin was utilized to select for the molecular chaperone plasmid
(MCP).
Table 2.5: Recombinant Proteins Utilized in this Dissertation. Cell types vary depending on the conditions necessary
for expression. * the molecular chaperone plasmid contained the genes for dnaJ, dnaK, GroEL and GroES. These
were used in combination with the plasmid for the αRNaseA FP to increase the amount of soluble protein.

Protein Type
VHHs (general)
αRNAseA-wt VHH
Green Fluorescent Protein
mruby, mAmetrine,
TSapphire
Biotin Ligase (BirA)
αCaffeine FP Fusions
αRNAse A FP fusions
pBB550

Vector

Inducer

pET21a+
IPTG
pET21a+
IPTG
pBBR1MCS4
IPTG
pBad
Arabinose
pET21a+
pET21a+
pET21a+
N/a

IPTG
IPTG
IPTG
IPTG

Cell type
BL21DE3
BL21DE3
BL21DE3
TOP10

Soluble/
Insoluble
Soluble
Insoluble
Soluble
Soluble

BL21DE3 pLysS
BL21DE3
BL21DE3 w/ MCP*
BL21DE3

Soluble
Soluble
Soluble
Soluble

4.2.1: Soluble Protein Expression
The DNA was introduced into the expression cell line by heat shock as described in
section 4.1. An overnight culture was created by inoculating 5 mL of LB containing the
appropriate antibiotic with one colony from the plate, or a small stab of culture from a -80°C
glycerol stock. Then, the culture was shaken overnight at 235 rpm and 37°C. A sub-culture was
created by transferring 1-2 mL of the overnight culture into 30-50 mL of fresh LB in a 250 mL
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baffled flask. The flask was shaken at 235 rpm and 37°C until the culture reached mid-log phase
(OD600= 0.6-0.8). Then, a 1 L culture was inoculated with 10 mL of the sub-culture in 1 L of
fresh LB in a 4 L culture flask. The large culture was shaken at 37°C and 235 RPM until it
reached mid-log phase (OD600=0.6-0.8). Next, the temperature was reduced to 20°C and protein
expression was induced with 0.5-1 mM IPTG. Fluorescent proteins in pBad vectors were
induced with 0.01% (w/v) arabinose. Protein expression was performed for 16-20 hours at 20°C,
and cells were harvested by centrifugation at 11,300 x g at 4°C for 20 minutes. Cell pellets were
stored at -20°C.
4.2.2: Cell lysis
Frozen cell pellets were resuspended in 40 mL of 10 mM Tris HCl buffer at pH 8.0.
Then, the pellets were sonicated on ice (alternating 30 seconds of sonication with 30 seconds of
rest) for a total of 2 minutes. The soluble and insoluble fractions were separated by
centrifugation for 20 minutes at 27,200 × g and 4°C. The soluble fraction was then loaded onto a
5 mL HiTrap IMAC column at 2 mL/min. Once the entire soluble fraction was loaded, HisTrap
running buffer (50 mM sodium phosphate, 500 mM sodium chloride, and 20 mM imidazole, pH
8.0) was flowed over the column once the absorbance at 280 nm baselined. The protein was
eluted by a stepwise increase of the imidazole concentration from 20 mM to 500 mM. Then, the
protein-containing fractions were combined and the UV absorbance was determined. The protein
concentration was determined by the extinction coefficient of the protein, listed in Appendix A.
Size exclusion chromatography was performed after HisTrap purification. Protein at a
concentration of 1 mg/mL or higher was loaded onto the size exclusion column. Sample
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concentration, if necessary, was performed in 15 mL Amicon centrifugal filters with a 3 kDa
molecular weight cutoff. A HiPrep 26/10 Superdex 75 column was used to further purify the
protein by size exclusion using 20 mM Tris pH 8.0, containing 150 mM sodium chloride, as
mobile phase.
4.2.3: Insoluble VHH Purification
Since proteins that are expressed in inclusion bodies are only partially folded, a series of
washes were performed and chaotropic solutions applied, in order to unfold protein of interest.
After sonication, the soluble and insoluble fractions were separated by centrifugation at 7,310 ×
g for 15 minutes at 4°C. The pellet was saved and three washes were performed as described in
Table 2.6.
Table 2.6: Solutions Utilized to Wash Inclusion Bodies of Insoluble Proteins. Pellets were resuspended in the same
solutions, followed by centrifugation at 7310 x g for 15 minutes.

Wash Number
1
2
3

Solution
50 mM Tris pH 8.0, 2% (w/v) deoxycholic acid, 5 mM EDTA
Water
10 mM Tris pH 8.0

To unfold the proteins, the pellet was dissolved in 50 mM sodium phosphate, pH 7.4,
containing 6 M guanidine HCl, 300 mM sodium chloride, 2 mM glutathione reduced, and 0.2
mM of oxidized glutathione. Then, the solution was centrifuged and the unfolded protein in the
soluble portion was saved. The protein was refolded by rapidly diluting it into a 10 time volume
of 20 mM Tris, pH 7.4, containing 2 mM reduced glutathione and 0.2 mM oxidized glutathione.
To prevent aggregation, the solution was rapidly stirred while the unfolded solution was being
added. Then, the protein solution was stirred overnight at 4°C.
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Aggregated material was removed by centrifugation at 15,300 × g for 20 minutes at 4°C.
The supernatant was decanted into a large beaker and loaded onto a 5 mL HiTrap column
connected to a peristaltic pump at 4°C and 5 mL/min. Then, the protein was eluted with a
stepwise increase to 500 mM imidazole. After the protein was eluted, it was purified on a
HiLoad Superdex 75 prep grade size exclusion column.
4.2.4: Expression and Purification of fluorescent proteins (pBad vectors)
All genes encoding the fluorescent proteins used here were obtained from Addgene. The
GFP plasmid (pAKgfp1) was a gift from Attila Karsi (Addgene plasmid #14076).52 The pBadmAmetrine1.1 was a gift from Robert Campbell (Addgene plasmid #18084).53 The Michael
Davidson lab gifted the mRuby pBad plasmid (Addgene plasmid #54763) and the mT-SapphirepBad plasmid was gifted from both Robert Campbell and Michael Davidson (Addgene plasmid
#54571).53
Overnight cultures and sub-cultures were made with LB as described in section 4.2.1.
The cultures were shaken at 37°C until the OD600 reached 0.6-0.8. It has been shown that glucose
inhibits arabinose induction, and that higher yields are obtained with minimal media instead of
rich media.54 M9 minimal media containing 20% casein, was utilized using glycerol as a carbon
source to prevent inhibition of arabinose induction. Once the large cultures reached mid-log
phase, the temperature was dropped to 20°C and protein induction was initiated with 0.01%
(w/v) L-arabinose. Culture temperature was maintained at 20°C overnight, after which the cells
were harvested by centrifugation and purified as described above for soluble proteins.
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4.2.5: Co-Expression of Molecular Chaperones with αRNaseA FP
Due to solubility issues with the expression of αRNaseA-FP fusion, a molecular
chaperone plasmid was obtained to co-express with the protein to increase the soluble protein
yield. Plasmid pBB550, containing the dnaK, dnaJ, and GroESL system, was a gift from Bernd
Bukau (Addgene plasmid #27396). The plasmid was isolated by streaking a plate with the stab
culture, making overnight cultures, and isolating the DNA with a Wizard Miniprep kit. The
Inoue method for creating competent cells was followed. 55
The DNA for the αRNAseA-fusion proteins was heat-shocked into the pBB550
BL21DE3 competent cells. Then, expression was performed as described by de Marco.56 Briefly,
the cells were expressed containing the dual antibiotics to select for cells containing the MCP
and the αRNAseA fusion protein. Following the same guidelines as for the WT expression, cells
were grown in a sub-culture and used to inoculate the larger culture after the sub-culture reached
the mid-log phase. Then, expression of both of the plasmids was induced after the large culture
reached mid-log by adding 0.5-1 mM IPTG. After 16-18 hour expression, the cells were
centrifuged down and resuspended in fresh LB containing 200 μg/mL chloramphenicol to inhibit
cell growth. The cells were incubated for 2-4 hours at 20°C with shaking, and then centrifuged at
11,300× g at 4°C for 20 minutes. The cells were then frozen and processed as described for the
purification of soluble proteins.
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5: Polyclonal Antibody Production
5.1: Preparation of Hapten-Protein-Conjugates
5.1.1: Derivatives of Hemin and Cholic Acid

Figure 2.2: Activation of the Carboxylic Acid Functionality of Cholic Acid. In the presence of DCC, an NHS ester is
formed, which can react in a subsequent reaction with amines on the surface of proteins. This type of reaction was
also performed with hemin.

In order to produce protein-conjugates of hemin and cholic acid, respectively, their
carboxylic acids were first activated to NHS-esters. In 50 mL of DMF, 506 mg of hemin, 156 mg
of DCC and 8.8 mg of sulfo-NHS were combined. The reaction then proceeded at room
temperature for 2 hours, and the precipitate from DCC was removed by decanting over filter
paper. The supernatant of the reaction was flash frozen with liquid nitrogen and lyophilized to
dryness. Once dry, the product was resuspended in dry DMF and a 50 molar excess of the
activated hapten was added dropwise to 100 mg of BSA at 10 mg/mL in PBS. The remaining
product was added to 20 mg of KLH at 5 mg/mL in PBS. The protein was allowed to react with
the activated hemin and cholic acid, respectively, at 4°C overnight while rotating end-over-end.
Then, the derivatized proteins were dialyzed against three changes of PBS to remove excess
unreacted hapten. The number of hemin groups was estimated spectrophotometrically by
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determining the absorption of the conjugate after dialysis and using the extinction coefficient of
heme at 400 nm (11 ×104 M-1 cm-1). 57 It was determined that there were approximately 8
molecules of hemin bound per molecule of BSA.
5.1.2: Derivatives of Pregnenolone
The ketone at carbon 20 of the aliphatic side chain of pregnenolone was first reacted in a
reductive amination with ε-aminocaproic acid and sodium cyanoborohydride. To a 250 mL
round bottom flask, 254 mg of pregnenolone and 210 mg of ε-aminocaproic acid were added in
35 mL of methanol. The reaction mix was sparged with nitrogen for 30 minutes. Afterwards, 48
mg of sodium cyanoborohydride were added. The solution was heated to 60°C and refluxed for
12 hours. Afterwards, 51 mg of sodium cyanoborohydride were added to ensure successful
reduction. The reaction continued refluxing for another 12 hours. Then, the sample was dried
under vacuum to remove the solvent. Completion of the reaction was tested by TLC using a
solution of phosphoric acid in water (1:1) for detection of underivatized steroid.58 The product
was washed with water to remove unreacted ε-aminocaproic acid. After flash freezing and drying
under vacuum, the reduction was confirmed with H1 and C13 NMR, observing the disappearance
of the ketone and the appearance of the secondary amine.
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Figure 2.3 :Reduction Amination of Pregnenolone with ε-Amino Caproic Acid. In order to couple pregnenolone to a protein
carrier, the ketone was reacted with ε-amino caproic acid, and the resulting Schiff Base reduced to a secondary amine. The
carboxylic acid was then activated with NHS/DCC for further reaction with accessible amines on proteins .
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In order to activate the carboxylic acid, 75 mg of product were reacted with 264 mg DCC
and 580 mg NHS at room temperature in DMSO overnight while rotating end-over-end. The
product was vacuum-filtered through a Buchner funnel to remove the insoluble precipitate,
followed by lyophilization to dryness. Afterwards, the product was resuspended in 8 mL of
DMSO, and 4 mL of the solution were added to 10 mL of BSA (at 5 mg/mL) in PBS and 4 mL
were added to KLH (at 2.5 mg/mL) in PBS. Both mixtures were rotated at 4°C overnight for 24
hours. To remove excess unreacted haptens, the proteins were dialyzed against PBS. MALDI
was used to confirm the coupling of pregnenolone to protein by comparing unconjugated BSA
with the pregnenolone-derivatized protein. MALDI results indicated that there were
approximately 4 molecules of pregnenolone per molecule of BSA.
5.2: Immunizations
All work involving rabbits was approved by NIU’s Institutional Animal Care and Use
Committee (ORC #LA13-0016). Four female 12 week old New Zealand white rabbits were
obtained from Covance (Denver, Pennsylvania) and allowed to acclimate for two weeks before
wiffle balls were surgically implanted beneath their skin by the University Veterinarian. Once
completely healed, immunizations were performed on two-week intervals with the KLH-hapten
conjugates. A total of 100 ng of immunogen was injected per animal, using multiple injections
sites. The first immunization was performed with the immunogen in CFA. Two weeks later, the
same amount of immunogen was injected using ICA as adjuvant. Finally, a booster injection was
performed with the same amount of immunogen in sterile PBS. Prior to each immunization, a 12 mL sample of interstitial fluid was drawn from the wiffle ball, and used to follow the immune
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response of each animal. Samples were centrifuged at 200 ×g for 30 minutes and frozen until
tested.
5.3: Antibody collection and ammonium sulfate precipitation
Two weeks after the last immunization, immune responses were tested by noncompetitive ELISA. Additional samples were drawn from the wiffle balls of the rabbits no more
than once a week to obtain larger amounts of antibody. Purification of antibody by ammonium
sulfate precipitation was adapted from Harlow and Lane.59 Collected interstitial fluid (ISF) was
centrifuged at 200 ×g for 30 minutes at 4°C. The supernatant was transferred to a 50 mL conical
and a saturated solution of ammonium sulfate was added dropwise while stirring until the
solution reached 45% ammonium sulfate. After stirring overnight, the protein suspensions were
centrifuged at 3,000 ×g for 30 minutes. The supernatant was removed and frozen at -20°C. The
salted out protein was resuspended in PBS, with 1/3 of the original volume, and extensively
dialyzed against PBS. The antibodies were further purified by affinity chromatography as
described below.
5.4: Coupling of Haptens to Activated Support Material
The hydroxyl groups on Sepharose 4ClB were activated with disuccinimidyl carbonate
(DSC) in the presence of dimethylaminopyridine (DMAP) in dry acetone as described by Miron
and Wilchek (Figure 2.4).60 Following a 1-2 hour incubation at 4°C, the support material was
washed with successive volumes of cold dry acetone, 5% acetic acid in dioxane, and methanol. A
small portion of support was tested for degree of activation by cleaving the NHS groups with
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0.25 M ammonium hydroxide and measuring the absorbance at 261 nm. Using the extinction
coefficient of 10,000 M-1 cm-1, the degree of activation in μmoles/g of support material can be
determined. Typically, activations yield between 10-40 μmoles/g of support.60

Figure 2.4: Activation of Hydroxyl Groups on the Surface of Appropriate Chromatographic Support Materials with
DSC. In the presence of DMAP, a strong base, the hydroxyl becomes a nucleophile and attacks the electrophilic
carbonate carbon, releasing an N-hydroxysuccinimide moiety.

Once activated, the Sepharose Cl4B was reacted with 1,6-diamino hexane in dry DMF
for 2 hours at room temperature to create a primary amine on the support material. Released
NHS and excess 1,6-diamino hexane was removed by vacuum filtration on a glass frit and
washing with dry DMF. Then, the NHS-Activated cholic acid or hemin was added in a 10 ×
molar excess over the number of active groups to the support material in DMF and allowed to
react at room temperature for 2 hours, creating the hapten-derivatized support material, seen in
Figure 2.5. The support material was washed with copious amounts of potential elution solvents,
which were determined as described in section 5.5, and alternating washes with water. Then, the
support material was stored until further use at 4o C in deionized water containing azide to
prevent microbial contamination.
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Figure 2.5: Coupling of Diamino Hexane to DSC-activated supports and Derivatization with Cholic Acid.

5.5: Determination of Elution Conditions for Affinity Chromatographic Antibody Purification
In order to identify suitable elution conditions for the affinity chromatographic
purification of polyclonal antibodies on hapten-derivatized Sepharose, microtiter plates were
coated with hapten-deivatized BSA, blocked with gelatin, and incubated with interstitial fluid
samples as described for the general non-competitive ELISA procedure in 6.1. Then, wells were
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filled with 100 μL of a variety of possible elution solvents, and incubated for 30 minutes at room
temperature with gentle agitation. Following washing with PBS-T, and incubation with HRPconjugated secondary antibody, the substrate OPD was added, and the absorbance at 490 nm
determined. Potential elution solvents were assessed based on their ability to remove antibody
from the hapten-derivatized solid phase, i.e., the extent the corresponding absorbance readings
were decreased in comparison to control wells incubated with PBS.
5.6: Affinity Purification of Polyclonal Antibodies
Ammonium sulfate precipitated antibodies were resuspended and dialyzed against PBS as
described in section 5.2. Since, prior to use, the support material was stored at 4°C in PBS
containing azide, it was first washed with PBS before addition of the polyclonal antibody
solution. The suspension was reacted in batch under gentle rotation at room temperature for 2
hours or overnight at 4°C. Then, the support was poured into a glass column and unbound
protein was eluted with PBS. PBS washings continued until a baseline was reached at 280 nm.
To elute bound polyclonal antibodies, the appropriate elution condition (as determined by
the procedure described in section 5.5) was applied using a peristaltic pump, and 1 mL fractions
were collected in microcentrifuge tubes. The absorbance of all fractions at 280 nm was
determined; antibody-containing fractions were pooled and dialyzed against PBS. If desired,
antibodies were concentrated using an Amicon 15 mL filter with a 100 kDa cutoff, and stored at
-20°C until further use.
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6: Techniques used to assess ligand binding:
6.1: Enzyme Linked Immunosorbent Assay (ELISA)
Maxisorp 96-well polystyrene plates were coated overnight at 4°C with 100 μL/well of
the antigen of interest at 1-5 μg/mL in 50 mM sodium carbonate buffer pH 9.6. Then, wells were
washed three times with PBS-T. To block unoccupied binding sites, the plates were incubated
with 1% gelatin in PBS-T for 2 hours at 37°C. Following another wash step, 100 μL/well of
antibody-containing solution was applied, and plates were incubated at 37°C for 2 hours.
Following another washing step, 100 μL/well of the appropriate detection reagent was applied:
For detection of biotinylated reagents, a 1:5000 dilution of Strep-HRP in PBS was applied. For
detection of polyclonal antibodies, an HRP-labeled goat anti-rabbit secondary antibody was used
at 5 μg/mL. Following incubation at 37°C for 2 hours and another washing step, 100 μL/well of
substrate solution (8 mg of o-phenylenediamine (OPD) in 20 mL of citrate-phosphate buffer, pH
5.4, containing 13 μL of 30% hydrogen peroxide) was added. Color development progressed for
a maximum of five minutes and was stopped by adding 100 μL/well of 1 M sulfuric acid. UVabsorbance at 492 nm was determined using a FLUOROstar plate reader.
6.2: Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) was used to determine binding constants of the
VHHs and VHH protein fusions. The binding constant can be determined based on the Gibbs
free energy equation (Eq 2.1):
∆G° = ∆H° − T∆S° = −RTln𝐾𝑎

Eq. 2.1
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Where ΔG° is the standard free energy change of the reaction, ΔH° is the standard enthalpy
change, T is the temperature in Kelvin, Ka is the association binding constant and R is the
universal gas constant (1.99 ×10-3cal mol -1 K-1).
To prepare a protein sample for ITC, the protein concentration was determined
spectrophotometrically at 280 nm using Lambert-Beer’s law. The appropriate protein
concentration correlates to the C value, which is seen in Eq. 2.2
𝐶 = 𝐾𝑎 × [𝑝𝑟𝑜𝑡𝑒𝑖𝑛] = 10 − 1000

Eq. 2.2

Using a C value between 10-1000 ensures that the thermogram will have acceptable curvature
for evaluation.61 If necessary, protein samples were concentrated in Amicon 3.5 kDa cutoff
centrifugal filters. Then, the samples were dialyzed against the buffer used for ITC evaluation
(typically PBS) for a minimum of 6 hours at 4°C while stirring. Following dialysis, the protein
sample was centrifuged at 20,400×g for 10 minutes at 4°C to remove protein aggregates.
Following re-determination of the protein concentration, the ligand concentration was prepared
based on the following equation:
[𝐿𝑖𝑔𝑎𝑛𝑑] = 10 × 𝑁 × [𝑃𝑟𝑜𝑡𝑒𝑖𝑛]

Eq 2.4

Where N is the anticipated stoichiometry between the protein and the ligand. The ligand was
dissolved in the same buffer as used for dialyzing the protein, and samples were degassed for 15
minutes at RT. The sample cell was washed with the dialysis buffer prior to placing protein into
the sample cell. Once equilibrated, ITC was performed as described in Table 2.7. ITC data was
evaluated using the MicroCal ITC addon for Origin (OriginLab Corporation, Northampton, MA).
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Table 2.7: ITC Settings for Investigating Binding Interactions between VHHs and their Ligands.
Injection #

Injection Volume (μL)

Duration (s)

Spacing (s)

Stirring (RPM)

1
2-28

2
10

4
20

240

307

7: Chemical and Enzymatic Protein Modifications
7.1: Chemical biotinylation
While a number of different conjugation chemistries can be used to biotinylate proteins, here, Nhydroxysuccinimide (NHS) biotin (Figure 2.4) was used for derivatization.62 The carbonyl on the
NHS ester is electrophilic and can be attacked by the nitrogens of primary amines, such as the Nterminus or the ε-nitrogens of lysine residues.

Figure 2.4: Structure of NHS-biotin. The electrophilic carbonyl is subject to nucleophilic attack by primary amines. In proteins,
the ε-amino groups of lysines and the N-terminus of the protein can react with NHS-biotin. When R= SO3, the compound is
sulfo-NHS, which has improved water solubility.

Chemical biotinylation was performed following the procedure presented in
Hermanson.62 In brief, proteins were dialyzed or resuspended in a non-amine containing buffer,
usually PBS. NHS-biotin was dissolved in dry DMF and added to the protein dropwise at a
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minimum of 10 times molar excess over the protein. Biotinylation was performed for 2 hours at
room temperature or overnight at 4°C with end-over-end rotation. Unreacted NHS biotin was
removed by extensive dialysis against PBS. Biotinylation was confirmed through a dot blot as
described in section 7.3.
7.2: Enzymatic Biotinylation
Biotin ligase (BirA) is an E. coli enzyme that selectively incorporates biotin at the lysine
residue within the Avitag sequence GLNDIFEAQKIEWHE. pET21a+- BirA was kindly
provided by Alice Ting (Addgene plasmid #20857).63 Once the protein containing the Avitag
sequence was expressed and purified as described in section 4.2, it was combined with 10 mM
ATP, 50 μM biotin and 10 mM magnesium acetate (Biomix A). For every 10 nmoles of Avitag
protein (at 40 μM), 2.5 μg of BirA was used.64 Protein mixtures were rotated end-over-end at
room temperature for a minimum of 2 hours to ensure complete biotinylation. Separation of the
biotinylated proteins from BirA was performed by size exclusion. In cases where the MW of
BirA and the biotinylated proteins were too similar, the (His)6 tag of the AviTag containing
protein was removed by TEV cleavage prior to biotinylation. BirA was then retained on an
IMAC column, while the biotinylated protein was collected from the flow through.
7.3: Confirmation of Biotinylation - Dot Blot Assay
Biotinylation was confirmed qualitatively by a dot blot assay on a nitrocellulose
membrane. Samples, as well as positive and negative controls, were applied as 3-5 μL drops and
allowed to dry for 30-60 minutes. Then, the membrane was washed for 30 seconds with a steady
stream of PBS-T and subsequently blocked with 1% gelatin in PBS-T at room temperature for 1

40

hour. Following a second wash, a 5 μg/mL sample of Strep-HRP was applied and the membrane
incubated for 30-60 minutes at room temperature. Following another washing step, visualization
was performed using a TMB solution (1-2 mg of TMB pre-dissolved in 1 mL of DMSO added to
a 20 mL citrate-phosphate buffer containing 13 μL of 30% H2O2). Dots were allowed to develop
for a maximum of 5 minutes and color development was stopped with a steady stream of
deionized water. The membrane was scanned or photographed.
8: Fingermark Visualization Techniques
8.1: Membrane Fingermark Tests
Marks were deposited on small nitrocellulose squares following a 10 second facial
grooming. To obtain aged marks, samples were covered with a glass petri dish and kept at room
temperature until development. Fresh marks were allowed to dry for 45-60 min, and then the
membranes were washed for 30 seconds with 0.05% Tween in PBS (PBS-T) and blocked for 1
hour at room temperature with 1% gelatin in PBS-T. Following another 30 second wash, marks
were incubated with the primary polyclonal antibody or a biotinylated VHH for 1 hour at room
temperature while rotating, and then washed for 30 seconds with PBS-T. Then, the visualization
reagent was applied: For biotinylated proteins, horseradish peroxidase (HRP)-labeled
streptavidin (Strep-HRP) was used. An HRP-labeled goat anti-rabbit secondary antibody was
used for polyclonal antibodies. Secondary antibodies were applied at a 5 μg/mL concentration
and incubated at room temperature for a minimum of 1 hour. Strep-HRP was incubated for a
minimum of 30 minutes at 5 μg/mL in PBS. A minimum of three test marks were developed per
experiment, one of which was only incubated with the secondary antibody/Strep-HRP as a
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negative control. After incubation with the HRP-labeled reagent and washing, the marks were
visualized with TMB solution containing 1-2 mg of TMB in a 0.2 M citrate-phosphate buffer pH
5.4 and 13 μL of 30% H2O2. Color development was monitored for 5 minutes and stopped with a
steady stream of DDH2O. Developed prints were scanned or photographed immediately after
color development.
8.2: Fluorescence Microscopy of Latent fingermarks on Glass with VHH-FP fusions
For testing visualization reagents on non-porous surfaces, fingermarks were deposited on
glass slides and visualized with VHH-FP fusion proteins. Fingermarks were placed onto glass
slides following a 10 second facial grooming and allowed to dry overnight at room temperature.
The marks were then submerged in a solution of the VHH-FP fusion protein in PBS at room
temperature with gentle agitation for 1-2 hours. For comparison, a separate mark was submerged
in a solution containing the fluorescent protein at the same concentration. Marks were visualized
using an epifluorescent microscope.
8.3: Forensic Fingermark Detection with Polilight PL550XL
Fingermark visualization using the VHH-fluorescent protein fusions, fluorescently
labeled polyclonal antibodies, and fluorescein labeled Concanavalin A were investigated on a
variety of different surfaces. Lyophilized Concanavalin A was resuspended at 10 mg/mL (10 mg
total) in PBS. A 10 molar excess (2 mg) of NHS-Fluorescein in 100 µL of dry DMF was added
dropwise to the protein. The reaction was performed overnight at 4°C with end-over-end
rotation. Polyclonal antibodies were reacted with NHS-Atto 610 in a similar fashion, following
manufacturer’s instructions.
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To test the developing capabilities of fluorescently labeled proteins, natural fingermarks
from a variety of different donors were obtained. The term “natural fingermark” indicates that no
handwashing or “charging” of the finger by facial grooming was performed prior to depositing
the mark. The marks were placed on nylon or PVDF membrane, as well as on aluminum foil.
Membranes were blocked with 1% gelatin in PBS for two hours prior to development.
Fingermarks were incubated with fluorescently labeled protein for 45 minutes prior to imaging.
Images were captured using the Poliview Polilight PL550XL.
9: Immunoaffinity HPLC
9.1: Production and purification of camelid anti-methotrexate VHH antibodies
All three antibodies employed in this study are variants of a previously produced antimethotrexate VHH.65 Kunkel mutagenesis66 was used to introduce a histidine at position 36 to
produce anti-MTX VHH M36H. Kunkel mutagenesis was then used to introduce a C-terminal
tetra-lysine tail and a C-terminal AviTag into anti-MTX VHH M36H to produce anti-MTX
M36H (cLys)4 and anti-MTX VHH M36H cAviTag, respectively. Anti-MTX M36H VHHs
were produced and purified according to the soluble expression and purification, section 4.2.1
and 4.2.2.
9.2 Stationary phase and column preparation
A batch of POROS-OH sufficient to pack three columns was activated for two hours with
DSC and DMAP as described in Miron and Wilchek.67 Following activations, subsequently
washed successively with dry cold acetone, 5% dioxane in acetic acid, methanol, and dry
isopropanol. The activated support material, which contained 26 μmol active sites/g as
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determined spectrophotometrically, was split into three equal parts of 2 g (wet weight) each,
which were derivatized as follows:
1) “Random” – The DSC-activated support material was incubated with 8.7 mg
(equivalent to about 630 nmoles of antigen-binding sites) of the anti-methotrexate antibody
named anti-MTX M36H (at 1.5 mg/ml in PBS containing 125 mM disodium sulfate) overnight at
4°C under rotation, followed by extensive washing with 100 mM Tris/HCl, pH 8, and PBS,
respectively, on a glass frit. Amount of VHH not bound to the support was estimated
spectrophotometrically by determining the absorbance of the flow-through at 280 nm.
2) “Tetra-lysine” – DSC-activated support was incubated with 9.2 mg (equivalent to
about 630 nmoles of antigen-binding sites) of anti-MTX M36H (cLys)4 (at 1.5 mg/ml in PBS
containing 125 mM disodium sulfate), and then processed as described for the “Random”
support.
3) “AviTag” – DSC-activated support was incubated with 14 mg of NeutrAvidin
(equivalent to about 630 nmoles of biotin-binding sites) overnight at 4 °C under rotation (at 10
mg/ml in PBS containing 125 mM disodium sulfate), followed by extensive washing with 100
mM Tris/HCl, pH 8, and PBS, respectively, on a glass frit. Then, the NeutrAvidin-derivatized
support was incubated overnight at 4°C under rotation with 10 mg (at 1 mg/ml in PBS) of
biotinylated anti-MTX VHH M36H cAviTag (equivalent to about 630 nmoles of antigen-binding
sites), followed by washing with PBS on a glass frit.
It should be noted that the in-batch-activation and immobilization employed here does
not allow for an accurate determination of the amount of protein actually bound to the support
material, as it is impossible to assess how much was lost during the process, e.g., by adsorption
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to the walls of the reaction containers. However, FAC was used to evaluate the number of active
binding sites on each support.
Each of the three VHH-derivatized support materials was slurry-packed at 160 psi into a
stainless steel column (3.2 mm x 50 mm) using an Alltech Slurry Packer Model 1666 (Alltech,
Deerfield, IL). No leakage of antibody was detected during column equilibration. The columns
were stored under azide-containing PBS at 4 °C only when not used for an extended period of
time.
9.3: Column Evaluation
To determine whether or not the VHHs immobilized on the column were able to bind to
methotrexate following coupling to the POROS, 20 μL injections of methotrexate and
methotrexate/aminopterin mix were performed at 1 mL/min at room temperature. Peaks were
detected by UV at 300 nm. Methotrexate binding was observed with a 20 mM sodium phosphate
buffer containing 150 mM sodium chloride at pH 7.4 and elution was performed with a 20 mM
sodium acetate buffer containing 150 mM sodium chloride at pH 4.0.
9.4: Chromatographic Conditions
To confirm that the produced columns were capable of retaining methotrexate and
purifying it from structural analogs, respectively, methotrexate (at 1 M in PBS) was injected
either alone or as a mixture with aminopterin and/or folate (at 0.5 M in PBS) in a volume of 20
l at RT and a flow rate of 1 ml/ml using PBS as mobile phase. Bound analyte was eluted by
switching to acetate buffer (20 mM sodium acetate, 150 mM sodium chloride), pH 4.0, followed
by regenerating the columns with PBS. Analytes were detected based on their UV-absorption at
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300 nm. The fastest baseline separations possible were obtained with the following protocol: 00.5 min PBS; 0.5-5.5 min acetate buffer; 5.5-9 min PBS.
For FAC analyses, columns were flushed at RT with methotrexate at concentrations
ranging between 0.1 and 10 M at 0.4 ml/ml, followed by eluting bound analyte with acetate
buffer, pH 4.0. These concentrations cover the range of about 1/10 to 10x the Kd for the
interaction between the antibody and methotrexate as determined by ITC. Columns were
subsequently regenerated with PBS. The 50% value of the maximum plateau was determined
from the centroid of the first derivative of the breakthrough curve.68 The retardation volume (V–
Vo) was determined by subtracting the 50% value of benzoic acid, which was not retained on the
columns, from the 50% value of the analyte. All data was determined at least in triplicate, and
standard deviations were smaller than 3%. The number of available binding sites (Bt) and the
dissociation constant (Kd) were then determined using the equation

1
𝐴𝑜 (𝑉−𝑉0)

=(

𝐾𝑑
𝐵𝑡

×

1
𝐴0

)+

1
𝐵𝑡

, where

[A]o is the concentration of methotrexate, V is the volume at half saturation, and Vo is the void
volume. The intercept of the extrapolated straight line on the abscissa corresponds to –1/Kd,
while the intercept on the ordinate corresponds to 1/Bt. Furthermore, the slope of the line is
equivalent to the ratio Kd/Bt. Thus, the total amount of immobilized active protein binding sites,
Bt, and the dissociation constant, Kd, can easily be derived from the double-reciprocal plot using
appropriate data evaluation programs68-69.
9.5: Frontal Affinity Chromatography
Each VHH column was subjected to frontal affinity chromatography. This was performed
by flowing concentrations of methotrexate between 0.1 μM and 10 μM methotrexate in PBS over
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the columns at 0.4 mL/min at room temperature. The concentrations of methotrexate correspond
to 1/10 to 10 times the Kd of the VHHs. The 50% value of the breakthrough curve is determined
using the maximum of the first derivative of the curve, or determining the volume at 50% of the
maximum value. The retardation volume, Vo, was determined with the 50% of the plateau of
benzoic acid, which does not bind to the VHHs. Each concentration was replicated a minimum
of three times. Using the retention volume minus the retardation volume (V-Vo) as well as the
initial concentrations of the concentrations, a double-reciprocal Lineweaver-Burke type plot was
used to extrapolate the Kd of the immobilized VHHs as well as the number of binding sites on
each column using the following equation:
1
Ao (V−V0)

K

1

1

= ( Bd × A ) + B
t

0

t

Eq. 2.5

Where Ao is the initial concentration, the volume is (V-Vo), Bt is the number of binding sites and
Kd is the dissociation constant. The Kds were compared to the ITC value and Bt were used to
determine which coupling was more efficient than the other.
9.6: Method validation
All three columns were evaluated for quantification of MTX dissolved in PBS (not
containing other analytes), and the method was validated for linearity, accuracy, precision, LOD,
and LLOQ.
A stock solution of MTX was prepared by dissolving 5 mg compound in 1 ml of DMSO,
and samples were prepared by dilution with 10 mM PBS.
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Accuracy was expressed as a percentage of the actual concentration divided by the
known concentration. The actual concentration was determined using the linear regression curve
of the calibration plot containing eight concentrations of MTX ranging from 0.04 to 12 μM with
five replications each. Precision was defined as percent coefficient of variance (CV, %) for each
sample. Intra-day assays consisted of five replications of five concentrations (200 nM, 475 nM,
810 nM, 1.1 μM and 4.74 μM), while inter-day assays analyzed the consistency between
injections performed on three different non-consecutive days. The LOD and LLOQ were
determined as the concentrations resulting in a signal/noise-ratio of 3/1 and 10/1, respectively.
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PART I:
SITE-DIRECTED IMMOBILIZATION OF A GENETICALLY ENGINEERED ANTIMETHOTREXATE ANTIBODY VIA AN ENZYMATICALLY INTRODUCED BIOTIN
LABEL SIGNIFICANTLY INCREASES THE BINDING CAPACITY OF
IMMUNOAFFINITY COLUMNS

1: Background
It has long been known that oriented immobilization of antibodies onto chromatographic
support materials can result in a considerably higher binding capacity of immunoaffinity
columns than random coupling70. Typically, site-directed strategies for the conjugation of
classically produced immunoglobulins target their Fc region (fragment crystallizable region),
which represents the stem of the Y-shaped molecule71 and is spatially separated from the
antigen-binding sites. Common methods include the formation of covalent bonds between the
carbohydrate chains in this area and the support material, or non-covalent binding of the
immunoglobulin to immobilized antibody-binding proteins such as protein A and protein G.72-75
Using a monoclonal antibody that stereoselectively recognizes L-amino acids as a model system,
it was shown that even higher column efficiency can be achieved if an antibody is first
biotinylated at its C-terminus using carboxypeptidase Y, and then non-covalently bound to a
streptavidin-derivatized support material.69 Compared to the 39 nmoles obtained with random
amine-coupling, this site-directed approach increased the number of available antigen-binding
sites by a factor of almost three, namely to 109 nmoles.
Advancements in the production of genetically engineered proteins, including antibodies
and antibody-fragments, over the last few decades have opened up new avenues for the
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incorporation of functionalities and tags for numerous applications, e.g., detection, purification
and conjugation/immobilization purposes.75-76
In 1990, Cronan reported the post-translational biotinylation of proteins containing amino
acid sequences that serve as recognition sites for naturally occurring biotin ligases.77 Nine years
later, Beckett et al. showed that the 14 amino acid long peptide GLNDIFEAQKIEWH is
sufficient to achieve efficient biotinylation of fusion proteins using the E. coli biotin protein
ligase BirA.78-79 This sequence, extended by a C-terminal glutamate, has been commercialized
under the name AviTag80, and has found applications ranging from protein purification and the
investigation of protein-protein interactions to the detection of antigens in enzyme-linked
immunosorbent assays. 81
Recently, Trilling et al. utilized the AviTag/BirA technology to achieve site-directed
immobil1ization of the variable domains of two camelid heavy-chain only antibodies (VHHs)
onto streptavidin-derivatized surface plasmon resonance sensor-chips.81 Utilizing several
variants of the original antigens, foot-and-mouth disease virus and a 16 kDa heat-shock protein
of Mycobacterium tuberculosis, respectively, they investigated the effect of antibody-orientation
and several analyte properties on biosensor sensitivity. While directed immobilization
consistently led to sensitivity increases, ranging from modest (1- to 2-fold) to significant (14fold), they came to the conclusion that the effect is more prominent for low-affinity than for
high-affinity systems.
VHHs represent the antigen-binding domains of a class of antibodies that was first
discovered in 1993 by Hamers-Casterman et al. in the sera of camels and llamas.82 These
camelid antibodies are composed of only two heavy chains, which do not require light chains for
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their interaction with antigens, as their three complementarity determining regions (CDRs) are
sufficient for target recognition. However, as in conventional antibodies, the antigen-binding site
is located towards the N-terminus of the heavy chains. While the complete heavy chain-only
antibody has a molecular weight of about 100 kDa, a VHH is significantly smaller with a MW of
about 15 kDa. Since VHHs are readily produced and modified by genetic engineering
techniques, expressed in good yield, and relatively robust and stable, they are particularly suited
for biotechnological applications, e.g., as capture reagents in biosensors and affinity
chromatography.83-84 In a previous publication, Franco et al. demonstrated that camelid singledomain antibodies can also be used for the immunochromatographic separation of small
molecules.84 A VHH directed against caffeine was linked to the high-flow through support
material POROS using random amine-coupling and utilized for the separation of several
methylxanthines by HPLC. 84-85
In the present investigation, an anti-methotrexate VHH was immobilized onto POROS
using three different conjugation approaches. The binding capacity of the respective
immunoaffinity columns was examined using frontal affinity chromatograph (FAC). The
columns were also evaluated for quantification of methotrexate.
Methotrexate (MTX), a structural analog of folate (Vitamin B9), is a potent inhibitor of
dihydrofolate reductase, an enzyme which reduces folate to its active form 5,6,7,8tetrahydrofolate (THF; 3.1). Since THF is an essential cofactor of a number of enzymes
participating in one-carbon transfer reactions in, e.g., the de novo biosynthesis of purines and
thymidylate, MTX has found widespread use for the treatment of various types of cancer,
autoimmune diseases, and the medical termination of pregnancy.86-87 Typical doses of weekly
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administered MTX range from 30 to 50 mg/m2, but much higher doses > 1 g/m2 may help to,
e.g., overcome drug resistance.88-89
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In routine practice, therapeutic drug monitoring is only used after high-dose MTX
infusions to assess drug elimination and avert excessive toxicity due to delayed elimination,
which is defined as plasma levels of MTX above 10, 1, and 0.1 μM after 24, 48, and 72 h after
administration, respectively.89 A number of techniques have been utilized to separate MTX and
its metabolites/structural analogs by reverse-phase, ion-pairing or ion-exchange chromatography,
with reported lower limits of detection ranging between 2 and 200 nM using ultraviolet
detection.90

2. Anti-MTX M36H VHH Initial Column Evaluation
To demonstrate, for the first time, the utility of immunoaffinity stationary phases for
separating MTX from structural analogs such as aminopterin and folate, the single-domain
camelid antibody anti-MTX M36H VHH was immobilized via random amine coupling onto the
high-flow through support material POROS-OH. The antibody, in which a methionine in
position 36 was mutated to a histidine, is a variant of a VHH that had been created originally by
grafting the three hypervariable loops of an anti-MTX VHH antibody onto the framework of an
anti-RNase A VHH.91 Using the X-ray crystallographic structure of the parent VHH, M36, due
to its proximity to methotrexate, was identified as a position that could likely perturb
methotrexate in a pH-dependent fashion.65 M36H would be predicted to undergo an
environmental change upon binding methotrexate, which may result in a change in its pKa value
that would produce a pH-dependent MTX binding event. While anti-MTX M36H VHH binds
MTX at neutral pH values (Kd ~ 1 μM), the dissociation constant increases significantly under
relatively mild acidic conditions, i.e., between pH 4 and 5.
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3: Frontal Affinity Chromatography of anti-MTX M36H columns
Based on the structure of the parent VHH, anti-MTX M36H VHH contains five surfaceexposed amino-groups, namely four ε-amines of lysine residues and the amino-terminal end of
the protein, highlighted in the Figure 3.2 below. Immobilization of the antibody in a random
manner onto DSC-activated support via these functional groups resulted in a stationary phase
that was capable of separating MTX from folate (data not shown) and its structural analog
aminopterin (Fig. 3.1 c), which lacks the methyl-group at N10 (Fig. 3.1c). While binding of MTX
was achieved using PBS at pH 7.4, the analyte readily eluted after switching to a sodium acetate
buffer of pH 4, as seen in Figure 3.3. The elution conditions did not harm the structural integrity
or antigen-binding activity of the antibody as the column performance did not significantly
change after more than 1000 separations, seen in Figure 3.4
The number of available binding sites and the apparent affinity of the VHH for
methotrexate was determined by FAC. Flushing the column with the analyte at varying
concentrations at a flow rate of 0.4 ml/min, elution profiles with fronts and plateaus typical for
FAC were obtained (Fig.3.5, a). The elution volume V at each analyte concentration was
determined from the centroid of the first derivative of the breakthrough curve, while Vo was
obtained using the volume at half-maximal saturation of the elution front of benzoic acid, which
was not retained on the column. A Lineweaver-Burk-type double-reciprocal plot of 1/[A]o (VVo) as a function of 1/[A]o gave a straight line as shown in Fig. 3.5a (y = 0.185x + 0.126; R2 =
0.999). The amount of immobilized active binding sites, Bt, and the dissociation constant, Kd,
were determined from the extrapolated intercepts on the ordinate and abscissa, respectively, and
from the slope of the straight line. It was found that random immobilization of the VHH yielded
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about 8 nmoles of available antigen-binding sites with an apparent Kd of 1.4±0.2 μM, a value
comparable with and within experimental error of the one determined by ITC (1.2±0.1 μM).

Figure 3.2: Crystal Structure of the Wild-Type Anti-Methotrexate VHH. The amine-reactive residues are highlighted
in red while methotrexate is highlighted in green. The C-terminus, where site-directed coupling will occur, is
highlighted in green.
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Figure 3.3: Separation of aMixture of Aminopterin and Methotrexate. Aminopterin elutes with the void volume
while methotrexate elutes with the application of ABS, pH 4.0
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Figure 3.4: Separation of Aminopterin and Methotrexate on the anti-methotrexate M36H Randomly Immobilized
Column after 81(blue line) and 1081 Injections (black line).

In an attempt to improve the binding capacity of VHH-based anti-methotrexate columns,
genetic engineering techniques were used to introduce a four-residue long tail of lysines at the
antibody’s C-terminus. It was expected that the larger number of amines in this region- the
yellow residue in Figure 3.2 would increase the probability of immobilizing the antibody in a
way that the antigen-binding site – which is located at the opposite, i.e., N-terminal side of the
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protein – would be accessible for interaction with the analyte. The addition of lysine residues in a
desired area of a protein’s surface by genetic engineering was previously utilized to facilitate
site-directed immobilization, improve stability, and increase the activity of some enzymes.92
Using FAC analysis (Fig.3.6 a and b; y = 0.097x + 0.0799; R2 = 0.999), it was determined that
immobilization of the tetra-lysine containing VHH onto DSC-activated POROS led to only a
slight increase in the number of available antigen-binding sites to about 10 nmoles, which
displayed an apparent affinity comparable to that determined by ITC (1.0±0.2 μM vs. 1.3±0.1
μM).
It should be noted that immobilization of proteins via surface-exposed amines using
amine-reactive chemistry is, in reality, not a truly random process, as the reactivity of individual
groups may depend on steric factors influencing their availability, and their electrostatic
environment. Since the N-terminal amino group, generally, has a pKa of 7.6-8, it is – compared
to the ε-amines (pKa of 9.3-9.5) – more likely to be deprotonated at pH values typically
employed with N-reactive chemistries, which makes it a better nucleophile 92-93However, a direct
comparison of the methotrexate elution profiles obtained with the anti-MTX M36H-based
column and the one prepared with the tetra-lysine variant shows a clear increase in retention time
on the latter (Figure 3.8 a and b).
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Figure 3.5: Frontal Analysis for the Anti-MTX M36H Column, Immobilized by Random Amine Coupling. a.
Frontal elution curves at various concentrations. b. determination of K d and Bt using a double reciprocal plot. Error
bars are hidden by symbols.
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Figure 3.6: Frontal Analysis for the Anti-MTX M36H tetralysine column. a. Frontal elution curves at various
concentrations. b. determination of Kd and Bt using a double reciprocal plot. Error bars are hidden by symbols.
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The strong interaction (Kd ca. 10-15 M) between biotin and the tetrameric protein avidin or
its analogs (such as streptavidin and NeutrAvidin) has found countless applications in
biotechnology, e.g., for the purification of biomolecules by affinity chromatography.94 Here, the
avidin-biotin system was used to immobilize a biotinylated variant of anti-MTX M36H noncovalently onto the chromatographic support material. In an attempt to obtain a number of
biotin-binding sites sufficient to immobilize the same amount of VHH as in the other two
columns, DSC-activated POROS was incubated with 14 mg of NeutrAvidin, a deglycosylated
form of avidin, but it was found that the support was already saturated with half the amount.
Rather than employing random, chemical labelling of the VHH using one of the many available
biotinylation reagents, it was decided to introduce the AviTag at the C-terminus and perform
site-specific enzymatic biotinylation of the lysine contained in this 15 amino acid long sequence
with BirA. Following incubation of the NeutrAvidin-derivatized support with the labelled VHH,
FAC was performed with the resulting column using MTX as analyte. Evaluation of the obtained
elution profiles at varying analyte concentrations (Figure 3.7a) using a double-reciprocal plot
(Figure 3.7 b; y = 0.028x + 0.024; R2 = 0.999) revealed a 4- to 5-fold increase in the number of
available antigen-binding sites (about 40 nmoles) compared to the other two columns. The
apparent affinity was determined to be comparable to that measured by ITC (1.2±0.1 μM vs.
1.5±0.2 μM). Taking into account that, compared to the other columns, only about half the
amount of VHH could be immobilized due to the shortage of biotin-binding sites on the
NeutrAvidin-derivatized support, one can argue that site-directed immobilization via a Cterminal biotin could result in as much as an 8- to 10-fold increase in binding capacity. The
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effect of the greater number of binding sites on the retention time is particularly evident in the
overlay plot that compares the elution profile of methotrexate on all three columns (Figure 3.7).

Figure 3.7: Frontal Analysis for the Anti-MTX M36H AviTag column. a. Frontal elution curves at various
concentrations. b. determination of Kd and Bt using a double reciprocal plot. Error bars are obscured by the symbols.
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Figure 3.8: Breakthrough Curves of Each Column at 1 μM. a). Random immobilization b) Polylysine Tail c) AviTag

4. Chemical versus Enzymatic Biotinylation
To investigate whether the increase in binding sites was indeed based on oriented
immobilization via the C-terminal biotin, or whether random biotinylation would yield the same
result, enough Neutravidin-coupled POROS was prepared for two columns. Using Nhydroxysuccinimide (NHS)-biotin, the anti-methotrexate M36H VHH was randomly biotinylated
via accessible amine groups and coupled to one column, whereas the other column was
derivatized with anti-methotrexate M36H AviTag that was enzymatically biotinylated. The same
number of moles of protein were applied to each column.
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To confirm that site-directed immobilization, rather than a random immobilization,
through an avidin-biotin interaction was necessary for the increase in binding capacity, enough
neutravidin-coupled support was prepared to create two columns. To one column, a chemically
biotinylated anti-methotrexate M36H VHH was immobilized. The other contained enzymatically
biotinylated anti-methotrexate M36H AviTag. The chemical biotinylation was performed using
NHS-biotin. A 10 molar excess of an NHS reagent is typically utilized to compensate for the
competing hydrolysis reaction. Therefore, it was assumed that the use of a 50 molar excess of
NHS-biotin over the VHH would ensure complete biotinylation of the five reactive amines
available for coupling.
Frontal analysis was performed on the two different columns. Overlays of the frontal
chromatograms at 1 μM shows the difference in the number of available binding sites between
the two biotinylation techniques, seen in figure 3.9. Interestingly enough, the randomly
biotinylated column has less binding capacity than the randomly immobilized column. It is
assumed that this decrease can be attributed to the burial of biotin within the biotin binding site
of neutravidin, increasing the steric hindrance and decreasing the flexibility of the protein. This
would cause additional accessibility issues, which would decrease the number of available
binding sites.
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Figure 3.9: Overlays of Chemical and Enzymatic Biotinylation at 1 μM. a) chemically biotinylatied b) random
coupling. c) enzymatic biotinylation. A shift to the right demonstrates an increase in the number of binding sites.

5: Method Validation
As proof of concept, all three columns, that is the columns investigated for optimization
of binding sites, were evaluated for quantification of MTX dissolved in PBS. The linearity of the
method was evaluated to demonstrate a proportional relationship of response versus sample
concentration over the working range. Calibration curves were prepared for all columns using 8
different concentrations. Regression analysis showed that all curves obtained by plotting the area
of the peak (y) versus the MTX concentration (x) are linear in the concentration range between
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0.04 and 12 μM, which covers the range relevant for therapeutic drug monitoring.89 The
following regression equations were determined – Random column: y = 27.74x – 2.26 (R2 =
0.993); Tetra-lysine column: y = 26.64x – 1.52 (R2 = 0.999); AviTag column: y = 24.77x – 0.75
(R2 = 0.999).
Accuracy and precision of the method using the three different columns were investigated
using five replicate determinations of five concentrations on the same day (intra-day), and a total
of three non-consecutive days (inter-day). Intra- and inter-day precision values were less than
11.6% CV for the random column, 7.9% CV for the tetra-lysine column, and 10.7% for the
AviTag-column. Intra- and inter-day accuracy values were 12.7% or lower for all columns. The
standard acceptance criterion for each back calculated concentration was a 15% deviation from
the normal value. Results are shown in Table 3.1. It is noteworthy that the LOD and LLOQ were
not dependent on the immobilization strategy and were found to be 40 nM and 132 nM,
respectively. This, however, is not surprising as it is reasonable to assume that, in a classical
affinity chromatography system with separate binding and elution steps, a higher number of
available binding sites resulting from oriented vs. random immobilization should primarily affect
the maximum amount of analyte that can be retained on a column, but have a lesser or no
discernible effect at lower analyte concentrations.
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Table 3.1: Accuracy and Precision for all Three Columns. Intra-day accuracy and precision was determined with the
averages of three consecutive samples on the same day.Inter-day accuracy and precision were evaluated on the
averages of triplicate injections on two non-consecutive days.

Concentration
200 nM
475 nM
810 nM
1.1 μM
4.74 μM

Random Column
Tetra-lysine Column
AviTag Column
Precision (%CV)
Precision (%CV)
Precision (%CV)
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day
1.8
11.6
4.7
7.9
2.9
10.7
2.9
4.9
3.4
6.2
1.6
7.2
1.9
4.9
4.2
6.4
1.5
2.7
1.8
5.6
2.5
5.5
3.6
5.9
0.5
4.6
2.8
5.9
3.7
4

Concentration
200 nM
475 nM
810 nM
1.1 μM
4.74 μM

Random Column
Tetra-lysine Column
AviTag Column
Accuracy (%)
Accuracy (%)
Accuracy (%)
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day
99.8
93.1
99.0
99.2
101.6
101.2
100.2
104.6
92.4
90.9
104.3
95.6
109.2
112.8
97.0
98.3
102.6
103.9
97.9
106.5
99.0
94.7
99.1
100.0
92.0
90.7
101.0
96.4
100.4
102.0
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PART II
VISUALIZATION OF LATENT FINGERMARKS USING BIOLOGICAL AFFINITY
REAGENTS

1- Development of latent fingermarks - background
The development and enhancement of latent fingermarks is of vital importance for
criminal investigations.35 While there are a great number of techniques available, challenges with
regard to, e.g., the detection of aged marks or marks on difficult surfaces such as skin remain.
Also, many commonly employed procedures can only be performed in the laboratory and are not
suitable for in-the-field application. Therefore, the development of new methods that can
facilitate fingermark visualization by practitioners is of great interest.
The goal of this study was to develop new biorecognition-based reagents, in particular
antibodies, and test them for their utility to visualize latent fingermarks. Antibodies have been
previously used for targeting amino acids and proteins such as human serum albumin present in
fingerprints.35, 95 Drapel, et al. developed fingerprints using commercially available antibodies
against cathepsin, keratin and dermcidin.96 Since these proteins are essential for normal skin
function, it can be assumed that they would be present in secretions, and therefore in fingerprints.
Recently, it was found that immunolabeling is compatible with many common fingerprint
development techniques, such as ninhydrin staining, which increases the usefulness of this
technique for practical applications.27
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In addition to common substances found in fingerprint secretions due to the normal organ
function of the skin, other compounds specific to the individual and their lifestyle such as
methamphetamine have been targeted.97 However, reagents that are directed against ubiquitous
components contained in prints should have much wider applicability, and targeting multiple
components simultaneously might increase the success rate of visualization and potentially
increase the information that could be gathered, e.g., use of cocaine or opiates.36, 98
Here, both components present in fingermarks as a result of normal skin function as well
as metabolites, which are the result of an individual’s lifestyle, were targeted. Antibodies were
produced by classical immunological as well as by molecular biological techniques. These
antibodies were purified, their binding properties characterized, and their utility for the
visualization of latent fingermarks tested.
2: Classically Raised Antibodies
2.1: Anti-Cholic Acid Antibodies
It has been discovered that about 2-3% of the lipids present in sebum secretions are made
of cholesterol and cholesterol esters.28 Cholesterol is most likely stemming from the blood
circulation rather than being synthesized by any of the glands, and is found in both eccrine and
sebaceous secretions.28 Cholesterol esters are particularly prevalent on the surface of the skin
due to bacterial esterification reactions of fatty acids with cholesterol.28 Since cholesterol is
abundant on the surface of the skin and ubiquitous, it was assumed that it would be a good target
for antibody-based visualization of fingermarks.
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Cholesterol is an endogenous molecule with important physiological roles and a low
molecular weight of about 387 g/mol. Thus, it was necessary to couple it to protein-carriers in
order to produce immunogens that could raise an immune response in animals. However, besides
the hydroxyl-group at carbon 3, cholesterol lacks functional groups amenable to derivatization. In
addition, conjugation via the D-ring was desired in order to increase the chance of obtaining
antibodies that would primarily bind to the steroid nucleus rather than the side chain. As known
from Karl Landsteiner's work, the site of linkage between a hapten and carrier has a great influence
on antibody specificity, and the functional groups farthest from the carrier are most likely to be
involved in complex formation.9

Therefore, steroids structurally related to cholesterol but

comprising a site for conjugation via the alkyl side chain were identified. As seen in Figure 4.1,
cholic acid maintains the hydroxyl group of cholesterol with the steroid center and contains a
carboxylic acid for conjugation. The bile salts cholic acid and chenodeoxycholic acid are the main
products of cholesterol catabolism, and are produced in humans to emulsify dietary fats for
digestion.99 Bile acid production from cholesterol occurs in the liver and involves 17 different
enzymes.99-100 It is noteworthy that the physiological conversion of cholesterol to bile acids
includes a number of chemical changes such as the saturation of the 5,6-double bond, the
introduction of two hydroxyl groups (at 7α and 12α), oxidation of C24 to a carboxylate, as well as
epimerization of the 3β-hydroxyl group to 3α. Furthermore, it is important to realize that the
conformation with regard to the A and B rings changes from “5α” to “5β”.101
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Figure 4.1: Chemical Structures of Cholesterol (a) and Cholic Acid (b).

Since it is difficult to predict what effect these structural differences may have on antibody
specificity, cholic acid is commercially readily available, and its carboxyl group allows simple
derivatization utilizing carbodiimide chemistry, it was decided to use it for the production of
protein-conjugates. Furthermore, it is noteworthy that bile acids are also found in serum and that
gut bacteria can convert 5α-sterols to 5β-sterols.102
The carboxylic acid present in cholic acid allows for simple activation, allowing for
reaction with primary amines, i.e. the N-terminus and ε-amino nitrogens on lysine.
2.1.2: Polyclonal Antibody Production
One 16-week old New Zealand White rabbit was immunized with KLH-cholic acid as
described in Chapter 2, section 5.2. Three injections were performed in biweekly intervals, and
1-2 mL of ISF were collected over a period of 17 weeks to determine the immune response in a
non-competitive ELISA using a BSA-hapten conjugate as solid-phase coating. As seen in Figure
4.2 the animal showed a strong immune response and a sharp increase in the production of
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detectable antibodies within 4-6 weeks. Antibody levels persisted for the duration of the
experiment, i.e., at least 17 weeks.

Figure 4.2: Immune Response of a Rabbit Immunized with KLH-Cholic Acid. Antibody production was determined
in a non-competitive ELISA using BSA-cholic acid as solid phase coating and interstitial fluid, collected at the
indicated times, at a 1:10,000 dilution. Absorbances obtained on control wells coated with underivatized BSA were
subtracted. Data points are averages of triplicate determinations, and the error bars are the standard deviations of the
determinations. Missing error bars are obscured by the data point.

2.1.3: Antibody Purification
Once a positive immune response was confirmed, larger volumes of ISF were collected
and the antibodies contained therein were purified. Following ammonium sulfate precipitation,
the antibodies were resuspended in PBS and dialyzed to remove ammonium sulfate. To further
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purify the antibodies, a centrifugal filtration device with a molecular weight cutoff of 100 kDa
was utilized. Considering that the majority of contaminants remaining after the ammonium
sulfate precipitation are usually serum albumin (66.5 kDa)103 and transferrin (80.0 kDa),104 these
proteins would elute in the flow-through while the antibodies would be retained. The sample was
flushed with three to five times the sample volume of PBS to ensure removal of the contaminate
protein. Following, SDS Gel electrophoresis was performed to confirm purification. As seen in
Figure 4.3, the ultrafiltration step removed impurities still present after the ammonium sulfate
precipitation. The band at 150 kDa in lane 2 represents whole antibody molecules. However,
some of the antibodies dissociate even under reducing conditions, leading to the band at around
50 kDa, indicating the heavy chains. 105
2.1.4: Antibody Characterization
A non-competitive ELISA was performed to confirm the binding activity of the
purified antibodies using a BSA-cholic acid coating (Figure 4.4). The decrease in absorbance at
higher antibody concentrations is likely caused by a so-called “hook effect,” which may be
explained by steric crowding that prevents specific binding of antibody to the solid-phase
immobilized target
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Figure 4.3: Reducing SDS PAGE Analysis of the Anti-Cholic Acid Antibody Fractions following Ultrafiltration. 1.
MW Ladder 2. Filter-purified antibody 3. Supernatant from ammonium sulfate precipitation 4. Crude extract

.
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Figure 4.4: Non-Competitive ELISA Result Obtained with Purified Anti-Cholic Acid Antibody using a BSA-Cholic
Acid Coating. Dilutions of 1:100 to 1:10,000,000 of a 1.5 mg/mL stock were used. Wells containing underivatized
BSA served as controls, and the obtained absorbances were subtracted from the results obtained with the BSAhapten conjugate. Data points are means of triplicate measurements and error bars represent the standard deviations
at each dilution.

Prints, “charged” with facial grooming for 10 seconds prior to deposition, were placed on
nitrocellulose membranes and aged for five days. They were then developed using the anti-cholic
acid antibody, goat anti-rabbit HRP and TMB. Figure 4.5 shows the ridge pattern obtained in the
presence of anti-cholic acid antibody, while no ridge pattern was obtained for the control, which
was incubated with goat-anti rabbit HRP and TMB only.
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Figure 4.5: Membrane Prints Developed with Anti-Cholic Acid Antibodies. Left: Print developed with 0.15 mg/mL
anti-cholic acid, goat anti-rabbit HRP and TMB. Right: Print developed with goat anti-rabbit HRP and TMB as a
control.

2.2: Anti-Pregnenolone Antibodies
2.2.1: Pregnenolone and its Relationship to Cholesterol
Cholesterol is a precursor for the production of pregnenolone and the conversion into the
hormone is accomplished in three enzymatic steps.106 Pregnenolone is then utilized as starting
material for the biosynthesis of all other steroid hormons.106 Since pregnenolone differs from
cholesterol only in its side chain, and the two compounds are otherwise structurally and
sterochemically identical (Figure 4.6), it was decided to attempt raising antibodies that would
potentially not only bind to the hapten but also to cholesterol and additional sterols in skin
secretions. The carbonyl-group at C20, furthermore, represented the opportunity to readily
functionalize pregnenolone via reductive amination.
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Figure 4.6: Chemical Structures of Pregnenolone (a) and Cholesterol (b).

2.2.2: Functionalization and Coupling to Proteins.
Ketones spontaneously react with primary amines to create Schiff bases.107 However, the
creation of the Schiff base is reversible, but stable secondary amines can be obtained with an
appropriate reducing reagent.107 Here, pregnenolone was reacted with ε-amino caproic acid and
the resulting Schiff base was reduced with sodium cyanoborohydride. The mild reducing reagent
was preferred over, e.g., sodium borohydride to prevent over-reduction. Conversion of the
ketone to the secondary amine was confirmed by proton NMR (Figure 4.7)
The introduced carboxyl-group was then converted to an NHS-ester to allow coupling to
the proteins BSA and KLH. Due to the lack of an appropriate chromophore that would have
allowed simple UV-spectroscopic assessment of the coupling success, matrix-assisted laser
desorption ionization mass spectrometry (MALDI) was performed. MALDI analysis is typically
used for protein analysis because it is considered a softer ionization technique.108 This leads to
1+ and 2+ charges, rather than larger charged species, such as 8+ or 9+. Furthermore, the
molecules ionized in MALDI stay intact, leading to highly accurate molecular weights.109 This
allowed for a direct comparison of the BSA-hapten conjugate and underivatized BSA (Figure
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4.8). The average mass of the BSA-pregnenolone conjugate was determined to be 69,143 amu,
while the average BSA mass was 67,128 amu. Considering the mass of pregnenolone (413 amu),
it was determined that approximately 4 hapten-molecules were bound per molecule of BSA. Due
to its complex multi-subunit structure, no MALDI analysis was performed with KLH, but it was
assumed that the hapten-density was similar to the one obtained with BSA.
2.2.3: Polyclonal Antibody Production
Two 16-week old female NZW rabbits (denoted Preg3 and Preg4) were immunized with
KLH-pregnenolone as described in Chapter 2, section 5.3. Three injections were performed in
biweekly intervals, and 1-2 mL of ISF were taken over a period of 17 weeks to determine the
immune response in a non-competitive ELISA using the BSA-hapten conjugate as solid-phase
coating. As seen in Figure 4.8, the animals showed a strong immune response and a sharp
increase in the production of detectable antibodies within 6-8 weeks. Antibody levels persisted
for the duration of the experiment, i.e., at least 17 weeks.
2.3.4: Antibody Purification
Following large-scale collection of ISF, antibodies were precipitated by addition of
ammonium sulfate and subsequently dialyzed into PBS. Potential elution conditions for an
affinity chromatographic purification of the antibody were determined in a non-competitive
ELISA. Figure 4.10 shows the effectiveness of various solvents in removing antibody from
solid-phase immobilized BSA-pregnenolone acid in comparison to PBS. 100 mM citric acid was
determined to be the elution solvent of choice, due to concerns of denaturation with 6 M
guanidine hydrochloride.
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Figure 4.7: Proton NMR Spectrum Obtained Following Reductive Amination of Pregnenolone. Top: Product Bottom: Pregnenolone starting material.
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Figure 4.8: MALDI results Obtained with BSA-Pregnenolone (top) and Underivatized BSA (bottom). MALDI experiments were performed by Dr. Martha
Vestling at the University of Wisconsin-Madison.

79

80

Figure 4.9: Immune Response of a Rabbit (Preg3) Immunized with KLH-Pregnenolone. Antibody production was
determined in a non-competitive ELISA using BSA-pregnenolone as solid phase coating and interstitial fluid,
collected at the indicated times, at a 1:1,000 dilution. Absorbances obtained on control wells coated with
underivatized BSA were subtracted. Data points are averages of triplicate readings, and error bars show standard
deviations. Missing error bars are obscured by the data point. Similar immune responses were obtained with the
other pregnenolone-immunized rabbit (Preg4).
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Figure 4.10: Efficacy of Potential Elution Solvents as Determined by Non-Competitive ELISA. After binding of the
primary antibody, the microtiter plate was incubated with elution solvents for 30 min at room temperature. Antibody
which remained bound to the surface-immobilized BSA-pregnenolone was detected with HRP-labeled anti-rabbit
antibody. PBS was used as a reference buffer.

Sepharose was activated with DSC and derivatized with 1,6-diaminohexane, before the
NHS-activated conjugate of pregnenolone and ε-aminocaproic was bound to the support.
Affinity purification of the antibodies using this material was performed as described in section
Chapter 2, section 4.6. Figure 4.11 shows the chromatogram obtained upon switching to the
elution solvent. Antibody-containing fractions were pooled, dialyzed against PBS, and
concentrated by ultrafiltration. The efficiency of the purification was tested by SDS-PAGE under
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non-reducing conditions. As seen in Figure 4.12, the polyclonal antibodies were successfully
purified as indicated by the two bands at 150 kDa and around 45-50 kDa, where the lower band
is indicative of the heavy chains.105

Figure 4.11: Affinity Purification of Antibodies on Pregnenolone-Derivatized Sepharose. Absorbance of 1 mL
fractions was determined at 280 nm following the application of the elution solvent.
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Figure 4.12: Reducing SDS PAGE Analysis of Anti-Pregnenolone Antibody (from Preg3). MW ladder; 2. Crude
ISF; 3. Following ammonium sulfate precipitation; 4. Affinity-purified antibody. Similar results were obtained for
the other pregnenolone rabbit (Preg3).
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2.2.5: Characterization of Purified Antibodies
A non-competitive ELISA was utilized to ensure that antibodies purified from the
interstitial fluid retained their binding capacity for pregnenolone. As seen in Figure 4.12, the
antibodies from both rabbits were capable of binding to solid-phase immobilized BSApregnenolone.
2.2.6: Visualization of Latent Fingernmarks

The antibodies were labeled with Atto 610-NHS for visualization studies. The utility of
the anti-pregnenolone antibodies for the visualization of latent fingermarks was tested on
aluminum foil as well as PDVF membranes. Natural fingermarks are not charged by, e.g., finger
sweeping of the face in order to increase the amount of sebaceous secretions. Ridge patterns for
both a weak and strong donor on two different surfaces were clearly identifiable (Figure 4.14). In
order to test whether the interaction of the antibody with components contained in the
fingermarks was specific, marks were incubated with Atto 610-labeled antibody in the presence
of 500 μg/mL and 2000 μg/mL BSA-pregnenolone, respectively, deposited as a dot on the
membrane (Figure 4.15). The decrease in fluorescence intensity of the print with increasing
concentration of competitor as well as the strong fluorescence of the competitor-containing dots
indicates that the antibodies specifically bind to components contained in the fingermark.

85

Figure 4.13: Non-Competitive ELISA Results Obtained with Purified Anti-Pregnenolone Antibodies from Preg3
(top) and Preg4 (bottom), respectively, Using a BSA-Pregnenolone Coating. Dilutions of 1:100 to 1:10,000,000 of a
0.6 mg/mL stock of each were used. Wells containing underivatized BSA served as controls, and the obtained
absorbances were subtracted from the results obtained with the BSA-hapten conjugate. Data points are means of
triplicate measurements and error bars represent the standard deviations at each dilution.
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Figure 4.14: Development of Aged Fingermarks with Atto 610-Labeled Anti-Pregnenolone Antibody. Left: strong
donor print on aluminum foil, aged four weeks. Right: Weak donor on PVDF membrane, aged five weeks.
Fluorescence was excited using the Polilight PL550XL forensic light source at 590 nm and emission was recorded
using a 750 filter. Images provided by Dr. Xanthe Spindler.

Figure 4.15: Competitive Anti-Pregnenolone Prints .Fresh, split sweat prints developed with Atto-610 labeled antipregnenolone antibodies in the presence of BSA-pregnenolone (Left: 500 μg/mL; right: 2000 μg/mL) as competitor.
Fluorescence was excited using the Polilight PL550XL forensic light source at 590 nm and emission was recorded
using a 750 filter. Image provided by Dr. Xanthe Spindler.
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2.3: Anti-Hemin Antibodies
2.3.1: Polyclonal Antibody Production
Heme, specifically heme b, is the oxygen-binding cofactor in hemoglobin and
myoglobin,110 but also serves as prosthetic group in, e.g., complex III of the electron transport
chain. Besides heme b, hemes a and c also serve as prosthetic groups in a variety of other hemeproteins including Cytochrome C, Complex IV, several peroxidases (e.g., CYPs), Catalase, and
Nitric Oxide Synthase.
The ubiquitous nature of heme and the fact that hemoglobin can be targeted for the
detection of fingermarks, especially blood-contaminated ones,111 made heme an intriguing target
for antibody production. While antibodies to hemoglobin have been reported in the literature112114

and are commercially available, to the best of our knowledge, no antibodies to the prosthetic

group, heme, have been described yet.
In order to produce protein-conjugates, the carboxyl-groups on commercially available
hemin, which contains a ferric central iron and a chloride ligand, were converted to NHS-esters,
and the activated hapten coupled to KLH and BSA, respectively.
The strong color of the protoporphyrin ring system and the formed protein-conjugates
allowed for an easy estimation of the hapten-density at 398 nm, where heme has an absorbance
maximum. Based on the spectrophotometric analysis of the derivatized and underivatized BSA,
about 8 hapten-molecules were bound per protein molecule. It was assumed that the KLH
reaction, which occurred simultaneously, resulted in similar hapten densities.
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One 16-week old New Zealand White rabbit was immunized with KLH-hemin as
described in Chapter 2, section 5.2. Three injections were performed in biweekly intervals, and
1-2 mL of ISF were collected over a period of 17 weeks to determine the immune response.
Analogous to the procedure described for the production of anti-cholic acid and antipregnenolone antibodies, the immune response was assessed by testing ISF in a non-competitive
ELISA using the BSA-hapten conjugate as solid-phase coating (Figure 4.16). The amount of
detectable antibody significantly increased after about 8-10 weeks and seemed to approach a
plateau towards the end of the experiment, i.e., 17 weeks. A possible explanation of the
unusually large standard deviations as well as the overall lower apparent absorbances (compared
to, e.g., the results obtained with anti-cholic acid and anti-pregnenolone antibody samples) could
be that some of the antibodies contained in the ISF reacted with hemoglobin/heme released by
lysed red blood cells during sample collection
2.3.2: Antibody Purification
Larger volumes of ISF were collected and the antibodies contained therein were purified
by ammonium sulfate precipitation and affinity chromatography. For the latter, NHS-activated
hemin was covalently bound to aminated Sepharose 4ClB as described in Chapter 2, section5.4.
Potential elution conditions were determined in a non-competitive ELISA. Figure 4.17
shows how effective various solvents were in removing antibody from solid-phase immobilized
BSA-hemin in comparison to PBS. Although guanidine had the strongest effect, it was not
considered a viable option due to its potential to irreversibly denature the antibody. The next
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most effective solvents were 100 mM glycine, 100 mM citric acid and 1 M acetic acid. Affinity
purification of the antibodies was performed as described in Chapter 2, section 2, 4.6

Figure 4.16: Immune Response of a Rabbit Immunized with KLH-hemin. Antibody production was determined in a
non-competitive ELISA using BSA-hemin as solid phase coating and interstitial fluid, collected at the indicated
times, at a 1:1,000 dilution. Absorbances obtained on control wells coated with underivatized BSA were subtracted.
Data points are means of triplicate measurements, and error bars indicate the standard deviations.
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Figure 4.17: Efficacy of Potential Elution Solvents as Determined by Non-Competitive ELISA. After binding of the
primary antibody, the microtiter plate was incubated with elution solvents for 30 min at room temperature. Antibody
which remained bound to the surface-immobilized BSA-hemin was detected with HRP-labeled anti-rabbit antibody.
PBS was used as a reference buffer.

Figure 4.18 shows the chromatogram obtained upon switching to the elution solvent, 1 M
acetic acid. Antibody-containing fractions were pooled, dialyzed against PBS, and concentrated
by ultrafiltration. The efficiency of the purification was tested by SDS PAGE under reducing
conditions. Figure 4.19 shows that the polyclonal antibody was successfully purified as indicated
by the two bands at 150 kDa and around 45-50 kDa, the latter indicating heavy chains.105
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Figure 4.18: Affinity-Purification of Anti-Hemin Polyclonal Antibody. Following the application of 1 M acetic acid,
the absorbance of collected 1 mL fractions was determined.
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Figure 4.19: Reducing SDS PAGE Analysis of the Anti-Hemin Antibody Purification.1. MW ladder; 2. Crude ISF;
3. Solution of antibody post-ammonium sulfate precipitation; 4. Affinity-purified antibody.
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2.3.3- Characterization of Purified Antibodies
A non-competitive ELISA was utilized to confirm that the antibodies purified from the
interstitial fluid were still able to bind to solid-phase immobilized BSA-hemin (Figure 4.20).

Figure 4.20: Non-Competitive ELISA Results Obtained with Purified Anti-Hemin Antibodies using a BSA-Hemin
Coating. Dilutions of 1:100 to 1:1,000,000 of a 1 mg/mL stock were used. Wells containing underivatized BSA
served as controls, and the obtained absorbances were subtracted from the results obtained with the BSA-hapten
conjugate. Data points are means of triplicate measurements and error bars represent the standard deviations at each
dilution.
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2.3.4: Visualization of Latent Fingermarks
The utility of the anti-hemin antibodies for the visualization of fingermarks was
confirmed using both sweat and blood prints on low-density polyethylene and aluminum foil,
respectively (Figure 4.21).

Figure 4.21: Visualization of Fingermarks Using Polyclonal Atto 610 NHS-Labeled Anti-Hemin Antibodies. Left:
Fresh latent sweat mark on LDPE membrane. Right: Blood fingerprint aged two weeks on aluminum foil.
Fluorescence was excited at 590 nm and emission was recorded using a 650 filter using the Polilight PL550XL
forensic light source. Image provided by Dr. Xanthe Spindler.
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3: VHH Antibodies for Fingerprint Detection
3.1: Anti-Caffeine VHH
3.1.1: Caffeine Consumption and its Implication for Fingermark Detection
Caffeine, along with its metabolites and structurally similar compounds, is a member of
the class of chemicals known as xanthines (Figure 4.20), more specifically methylxanthines,
which contain a methyl group linked to at least one of the ring nitrogens.115 Xanthines are the
precursor of uric acid and participate in the catabolism of nucleotides. Methylxanthines are
consumed through the diet - typically in the form of caffeinated beverages or chocolate.115 There
is evidence that humans have consumed methylxanthines for centuries in the form of coffee, tea
and cocoa, which remain the most important beverages for methylxanthine consumption
today.115-116
Following consumption, caffeine (Fig. 4.22, f) is absorbed within approximately 45
minutes and distributed throughout the body.13 It is predominantly converted into paraxanthine,
shown in Figure 4.22 c. A small portion is also metabolized to theobromine, displayed in Figure
4.22, d. However, theobromine is more predominant in chocolate than in coffee. Theophylline is
a drug that is administered for cardiorespiratory disorders and has similar pharmacokinetics and
pharmacodynamics to caffeine.117
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Figure 4.22: Structure of Some Xanthine Compounds. a) Xanthine. b) 1-methylxanthine, a product of the
metabolism of theobromine, caffeine and paraxanthine.118 c) Paraxanthine, d) theobromine, and e) theophylline are
the physiologically active dimethylxanthines; f) caffeine, the trimethylxanthine 119.

A recent study by Mitchell et al. reported that 85% of Americans, age 2 and older,
currently consume caffeine on a daily basis.116 Table 4.1 shows the concentration of
theobromine, caffeine and theophylline in a variety of different raw chocolate (cacao) products.
It was predicted that due to the widespread consumption of chocolate and other caffeinecontaining food products, a large percentage of fingermarks could be visualized using an anticaffeine antibody. Furthermore, the presence of caffeine in sweat and fingermarks had been
confirmed previously by GC/MS120 and LC/MS,121 making this approach appear all the more
feasible.
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Table 4.1: Xanthine Compounds Present in a Variety of Cocoa Products. Adapted from Franco, Nutrients 2013.115

Methylxanthines in Chocolate Products (mg/kg of sample)
Source (kg)
Theobromine (mg)
Caffeine (mg)
Theophylline (mg)
Raw Ground Paste
33,000
5600
200
Roasted Ground Paste
36,000
330
Below LOD
Cacao
26,000
240
Not detectable
Cocoa Butter
140
400
Below LOD
Baking Chocolate
10,040
1580
Below LOD
Milk Chocolate
1,004
56
Below LOD
Dark Chocolate
5000-7500
625-875
Not detectable
Moreover, the production of an anti-caffeine VHH had been previously reported by
Ladenson et al. and the sequence information of its CDRs used by the Horn group at NIU to
create a genetically engineered anti-caffeine VHH by grafting the CDRs onto an anti-RNAseA
scaffold.85 The binding characteristics of the anti-caffeine VHH to caffeine, theophylline,
paraxanthine and theobromine were previously investigated with ITC, and the apparent Kds were
determined to be 14 nM, 101 nM, 555 nM and 666 nM, respectively. The strength of interaction
between the anti-caffeine VHH and caffeine as well as its structural analogs, along with the
widespread consumption of caffeine, all were expected to facilitate fingermark development
using appropriately labeled anti-caffeine antibodies.
3.1.2- Proof-of-concept Investigation Using Biotinylated Antibodies
In order to test whether the anti-caffeine VHH could bind to targets deposited in a
fingermark, the antibody was biotinylated and its utility tested on nitrocellulose membranes.
Such porous membranes are known to be good fingermark substrates, as they non-specifically
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adsorb proteins and oils. Initial studies published on immunolabeling of fingermarks are,
therefore, often performed on membranes.36
Anti-caffeine is expressed as a monomer, however, it exists in solution as a dimer and,
subsequently, binds to caffeine as a dimer.85 Anti-caffeine was expressed and chemically
biotinylated as described in Chapter 2, section 7.1. For comparison, a covalent “tandem” dimer
was expressed, which contained a 20 amino acid linker consisting of four repeats of GGSSS
between the monomers. In addition, the tandem dimer contained an Avitag at the C-terminus,
which can be enzymatically biotinylated within the tag, as described in Chapter 2, section 7.2.
Prints deposited on membranes were incubated with the biotinylated VHHs, exposed to
streptavidin-HRP and visualized with TMB. As seen in Figure 4.23, visualization of marks with
good ridge detail was possible using the chemically biotinylated monomeric anti-caffeine VHH.
Neither of the two negative controls, i.e., marks developed in the absence of VHH but incubated
with Strep-HRP and TMB or TMB only, respectively, allowed visualization. It was furthermore
found that there was no discernible difference between enzymatically biotinylated tandem dimer
VHH or the chemically biotinylated monomer (data not shown). As the expression of the
monomer, however, resulted in higher yields, subsequent experiments were performed with this
variant.
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Figure 4.23: Fingermarks on Nitrocellulose Membranes. Left: Print visualized using chemically biotinylated anticaffeine VHH, streptavidin conjugated to horseradish peroxidase (Strep-HRP), and the substrate TMB. Center:
Membrane incubated with only Strep-HRP and TMB. Right: Membrane developed with TMB only.

3.1.3: Fluorescent Fusion Proteins
Due to the high sensitivity of detection that can be achieved with fluorescence-based
methods, fluorophores are widely used labels in, e.g., immunohistochemistry, cytology, and
analytical biochemistry.122-127 Commonly, small organic fluorescent probes are chemically linked
to proteins utilizing appropriate functional groups on the surface of the macromolecule, an
example being Fluorescein Isothiocyanate (FITC), which reacts with amines. More recently,
fluorescent proteins have been used for, e.g., in vivo cell tracking and Fӧrster resonance energy
transfer (FRET).47 The most prominent fluorescent protein, GFP, which was first investigated by
Osamu Shimomura as early as in the 1960s, is an auto-fluorescent protein that causes the
chemiluminescent glow of Aequeora Victoria jellyfish.47 By the late 1990’s, the crystal structure
of GFP had been solved and the protein recombinantly expressed in both mammalian and cell
bacterial cultures.47 Fluorescent proteins were also discovered in red coral as light harvesting
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proteins. Since the discovery of these auto-fluorescent proteins, many color variants have been
developed with different parameters, such as different molar absorptivities, excitation and
emission wavelengths, Stokes shifts, and brightness.
In order to facilitate the production of fluorescently-labeled VHHs and make a separate
chemical derivatization step unnecessary, fusion proteins with a number of fluorescent proteins
were generated, and their utility for the visualization of fingermarks tested.
A comparison of the fluorescent properties of fusion proteins utilized in this study is provided in
Table 4.2. Fluorescent proteins were selected based on their excitation and emission
wavelengths, as well as their Stoke shifts, which should be as large as possible to minimize
background. Also, brightness was an important factor as it increases the sensitivity of detection.
Table 4.2: Comparison of Different Fluorescent Proteins used to Create VHH Fusion Proteins for Fingerprint
Visualization. a Molar extinction coefficient. b Quantum yield. cBrightness is represented as a percentage of EGFP,
the optimized GFP. d Obtained from Cubitt, et al. 128. eObtained from Heim and Tsien 129. All other fluorescent
properties were obtained from reference 47. Green color represents the ideal parameter, which was defined as >100
nm Stokes shift and a brightness >100% compared to EGFP. Yellow represents sub-optimal parameters, i.e., A
Stokes shift of 20-50 nm Stokes and a brightness of 50-100% compared to EGFP.

Name
GFP

ε (M-1 cm-1)a

Φb

Brightnessc

Excit. (nm)

Emis. (nm)

Stokes (nm)

395, 475

509

114, 34

30,000d

0.77e

50

0.78

78

mAmetrine

406

526

120

45,000

T-Sapphire

399

511

112

44,000

0.60

79

mRuby

558

605

47

112,000

0.35
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The genes for the fusion proteins between anti-caffeine VHH and the fluorescent proteins
were created using overlap extension mutagenesis as described in Chapter 2, section 4.1. Once
insertion of the fluorescent protein gene into the appropriate plasmid was confirmed by
sequencing, each VHH-fusion protein was expressed and purified. The VHH-fluorescent fusion

101

proteins expressed in the soluble fraction as the wild-type VHH had were purified accordingly,
as described in Chapter 2, section 4.2. Prior to utilizing the fusion proteins for fingerprint
detection, the binding activity of the purified proteins was investigated using isothermal titration
calorimetry. All anti-caffeine fusion proteins were similar to the wildtype VHH with regard to
apparent Kd for caffeine, as well as stoichiometry, enthalpy and free energy of binding (Table
4.3). As an example, the ITC results obtained with the anti-caffeine VHH TSapphire fusion
protein are presented in Figure 4.24. The thermodynamic data obtained by ITC confirms that the
fluorescent anti-caffeine VHH fusion proteins are active and that the fluorescent protein
component does not interfere with ligand binding. Due to a lack of stability of the mRuby fusion
protein under the experimental conditions, they could not be tested by ITC.
Table 4.3: Summary of ITC Results Obtained with the Different Fusion Proteins of Anti-Caffeine VHH and
Fluorescent Proteins. Caffeine was used as ligand. WT data was published by Sonneson. 85

Name
Anti-Caffeine
WT
Anti-CaffeineGFP
Anti-CaffeinemAmetrine
Anti-CaffeineTSapphire

Kd,app (nM)
14.1 ± 1.6

N
0.496 ±0.002

ΔHobs( kcal/mol)
-72.2 ± 0.5

ΔG (kcal/mol)
-10.70 ± 0.06

10.5 ± 2.6

0.503 ±0.002

-54.2 ± 0.4

-10.90 ± 0.13

20.9 ± 2.6

0.581 ±0.002

-77.6 ±0.3

-10.47±0.07

7.6 ± 2.0

0.468 ±0.002

-74.2 ± 0.1

-11.06±0.14
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Figure 4.24: ITC Results Obtained with the Anti-Caffeine VHH-mAmetrine Fusion Protein and Caffeine.
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3.1.4: Fingermark Visualization Using Fluorescent Anti-Caffeine VHH Fusion Proteins
In order to test the utility of fluorescent anti-caffeine VHH fusion proteins for fingermark
visualization, marks were deposited on glass slides and incubated for a minimum of one hour
with the fusion proteins. GFP and mRuby fusion proteins were visualized with a Nikon
Epifluorescent microscope, using the GFP and TRITC filter sets, respectively. Figure 4.25
shows, as an example, a three-week aged print developed with the anti-caffeine-GFP. It is
noteworthy that GFP alone was not sufficient to achieve visualization of marks, as seen in Figure
4.25.

Figure 4.25: Fluorescence Image of a Fingermark Deposited on Glass and Visualized with Anti-Caffeine-GFP (left).
Incubation with GFP alone did not yield a ridge pattern (right). Fluorescence was excited for 1 second using the
GFP filter set (Ex: 470 nm, Em: 525 nm) on the Nikon E-600 Light microscope with a 0.6X objective. Images were
recorded with a Nikon F1lc digital camera system.
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Figure 4.26: Fluorescence Images of Marks Deposited on Glass and Visualized with the Anti-Caffeine VHH-mRuby
fusion protein (left) and mRuby alone (right). Fluorescence was excited for 1 second using the TRITC filter set (Ex:
545 nm, Em: 620 nm) on the Nikon E-600 Light microscope with a 0.6X objective. Images were recorded with a
Nikon F1lc digital camera system.

The fingermarks developed with the anti-caffeine GFP fusion protein showed clear
ridges, while GFP alone was not sufficient to develop a ridge pattern. This is in contrast to
results obtained with the fusion protein between anti-caffeine VHH and mRuby, where
considerable non-specific binding of the fluorescent protein to fingermarks was observed (Figure
4.26).
Subsequent investigations, undertaken by Dr. Xanthe Spindler at the University of
Technology, Sydney, further demonstrated the utility of the fluorescent anti-caffeine VHH fusion
proteins for fingermark visualization. However, as seen in Figure 4.27 besides GFP all
fluorescent proteins showed at least some non-specific interaction with the marks, the least being
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observed with TSapphire followed by mAmetrine. Also these experiments demonstrated strong
non-specific interaction between mRuby and fingermarks.

Figure 4.27: Fingermark Visualization using Various Fluorescent Anti-Caffeine Fusion Proteins. One side of a split
mark (left) was incubated with the fusion protein, the other (right) with the fluorescent protein alone. a. anticaffeine-TSapphire vs TSapphire. b. anti-caffeine-mAmetrine vs mAmetrine. c. anti-caffeine-mRuby vs mRuby.
The mAmetrine and TSapphire excitation was 450/530, while excitation and emission for mRuby was 530/610.
Fluorescence was excited using the Polilight PL550XL forensic light source. Image provided by Dr. Xanthe
Spindler.

In order to test how recent caffeine consumption effects the visualization, marks were
visualized with anti-caffeine-GFP for a period of five hours following consumption of a cup of
coffee. As seen in Figure 4.28, strong fluorescence is obtained within the first two hours, while
the signal intensity decreases after three hours, which may be explained with the catabolization
of caffeine, given that the half-life of caffeine is approximately 3.5 hours.130 The intensity
increase seen after four and especially five hours may be caused by metabolites of caffeine
formed and secreted after this time, which varied between subjects, but were observed between
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3-7 hours in fingerprints after consumption in the study by Kuwayama, et al.121 It is noteworthy
that such clear time-dependent intensity differences were particularly obvious for weak donors
(as shown in Figure 4.28). Strong and weak donors differ in the amount of material that is
deposited by a donor - the stronger the donor, the more material is deposited within the ridge
impression.

Figure 4.28: Marks Deposited by a Weak Donor at Different Times Following Consumption of 320 mL of
Cappuccino. Marks were visualized with anti-caffeine-GFP. Fluorescence was excited using the Polilight PL550XL
forensic light source at 430 nm and emission was recorded using a 530 nm. Images provided by Dr. Xanthe
Spindler.

Additional competitive tests were performed by introducing caffeine, paraxanthine and
theobromine into separate solutions of anti-caffeine-GFP (Figure 4.29). Following a two-hour
pre-incubation of the anti-caffeine GFP with the corresponding inhibitor, the prints were
developed. Comparison of the ridge patterns of the inhibited prints to the positive control, it is
evident that there is a reduction in the ridge pattern. This indicates that, when in the presence of
the inhibitor, that the anti-caffeine is binding to the inhibitor in solution, therefore resulting in a
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decrease in fluorescence intensity on the ridges. This suggests that the interaction of the anticaffeine VHH with the fingerprint is indeed a specific interaction.

Figure 4.29: All Prints Incubated with Anti-Caffeine-GFP and an Inhibitor. Inhibitors were at 10 mg/mL. a).
Caffeine b). Paraxanthine c). Theobromine. d). Positive control (no inhibitor)

3.2: Anti-RNaseA VHH
3.2.1: Targeting of RNases within the RNaseA Family
RNaseA is an enzyme that catalyzes the hydrolysis of RNA into smaller fragments. It has
been a popular model system for the investigation of structure-function relationship in
biochemistry and was one of the first proteins to have been crystallized.131 Though the members
of the RNaseA superfamily typically digest and degrade RNA, some human RNases have
evolved to have other functions instead, such as their involvement with angiogenesis, antiviral,
and antibacterial activities.132 In total, there are eight human RNases, with one of them being
RNase 7, which is an anti-microbial epithelial protein.132 RNase 7 acts upon gram-positive and
gram-negative bacteria, and causes 90% lethality when present at concentrations greater than 30
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nM.133 While it is capable of catalyzing the degradation of RNA, this function was shown not be
required for its antimicrobial activity.132 RNase7 is present in various epithelial tissues, e.g.,
nasal and bronchial tissues, as well as in keratinocytes of the skin.133
The gene of an anti-RNaseA VHH, originally directed against bovine pancreatic
RNaseA, was available in the Horn group at NIU. Due to the structural similarity within the
RNaseA superfamily, it was predicted that the anti-RNaseA VHH might be able to target RNases
present in skin secretions and, therefore, could be useful for the visualization of fingermarks.
3.2.2: Proof-of-concept Investigation Using Biotinylated Antibodies
A chemically biotinylated anti-RNaseA VHH was prepared by reaction with NHS-biotin.
Following confirmation of biotinylation by dot blot, the biotinylated VHH was utilized on fresh
charged fingerprints deposited on a nitrocellulose membrane. Streptavidin-HRP and the substrate
TMB were used for detection. As seen in Figure 4.30, visualization of marks with good ridge
detail was possible using the chemically biotinylated VHH, while neither streptavidin-HRP/TMB
or TMB alone were sufficient for detection.
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Figure 4.30: Fingermarks on Nitrocellulose Membranes. Left: Print visualized using chemically biotinylated antiRNaseA VHH, Strep-HRP and the substrate TMB. Center: Membrane incubated with only Strep-HRP and TMB.
Right: Membrane developed with TMB only.

3.2.3: Fluorescent Fusion Proteins for Visualization
The anti-RNaseA VHH was recombinantly fused with the fluorescent proteins GFP,
TSapphire, mAmetrine and mRuby. Following expression of the anti-RNAseA fusion proteins, it
was noted that the fusion protein remained in the insoluble fraction of the pellet. To increase the
yield of the soluble fraction, molecular chaperones were co-expressed. However, the yields were
extremely low. Reliable ITC could not be obtained, but ligand-binding was indicated by an
enthalpy peak (data not shown). Based on this, visualization of prints was attempted. Prints were
then deposited membranes and developed with the fluorescent anti-RNaseA fusion proteins
(Figure 4.31).
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Figure 4.31: Use of Anti-RNaseA-GFP with Fingerprints on Membranes. Left and middle prints were placed on a
nylon membrane, while the right one was on a PVDF membrane. Fluorescence was excited at 430 nm and emission
was recorded using a 530 filter using the Polilight PL550XL forensic light source. Images provided by Dr. Xanthe
Spindler.

3.3: Folate
3.3.1: Targeting Folate with an Anti-methotrexate VHH
As described in Part I, an anti-methotrexate VHH suitable for the chromatographic
separation of methotrexate, aminopterin and folate was generated. Since this antibody displays a
millimolar affinity for folate, it was predicted that it could bind to folic acid present in
fingerprints.
3.3.2: Proof-of-concept Investigation Using Biotinylated Antibodies
As a proof of concept, the anti-methotrexate VHH was chemically biotinylated with
NHS-biotin. Fresh, charged prints were incubated with the VHH and marks were visualized with

111

the help of streptavidin-HRP and the substrate TMB (Figure 4.32). Development of a
fingermark charged with sebaceous secretions gave clear details in comparison to the negative
controls. Because of the clear details obtained, an anti-methotrexate VHH GFP fluorescent
fusion protein was produced.

Figure 4.32: Fingermarks on Nitrocellulose Membranes. Left: Print visualized using chemically biotinylated antimethotrexate VHH, Streptavidin conjugated to Strep-HRP and the substrate TMB. Center: Membrane incubated
with only Strep-HRP and TMB. Right: Membrane developed with TMB only.

3.3.5: Fluorescent Fusion Protein
The fusion between the genes of anti-methotrexate and GFP was created using OEM
PCR, as described in Chapter 2, section 4.2. Once the insertion was confirmed by sequencing,
the fusion protein was expressed. Similar to the anti-caffeine GFP fusion protein, the expressed
anti-methotrexate GFP was soluble. ITC of the fusion protein confirmed a Kd,app value of 6 nM.
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Since the wild type anti-methotrexate had a Kd,app of 4 nM, the similar Kd,app of the fusion protein
suggests that the fusion does not affect ligand binding by the VHH.
To test the utility of the anti-methotrexate GFP fusion protein, fluorescent microscopy
was used to visualize prints developed with the anti-methotrexate GFP fusion protein. As seen in
Figure 4.33, prints deposited on glass slides could be visualized in the presence of antimethotrexate-GFP, whereas GFP alone was insufficient for detection.

Figure 4.33: GFP Fluorescence Images of the Anti-MTX GFP Fusion Proteins. Left: Three week aged print
developed with anti-MTX GFP. Right: two week aged print with GFP alone as a negative control. Fluorescence was
excited for 1 second using the GFP filter set (Ex: 470 nm, Em: 525 nm) on the Nikon E-600 Light microscope with a
0.6X objective. Images were recorded with a Nikon F1lc digital camera system.

4: Concanavalin A
4.1: Background
Concanavalin A (ConA) is a lectin, i.e., carbohydrate-binding protein, isolated from the
Jack Bean Canavalia Ensiformis.134 It is one of the most extensively studied lectins and requires

113

metal to bind to carbohydrates.135 ConA binds the strongest to a triple mannose trisaccharide,
with a Kd of 709 nM,136 but also binds to a variety of other sugars.137 The molecular weight of
ConA is 25.5 kDa per monomer, and at physiological pH it exists as a tetramer. When it binds to
glycolipids and glycoproteins located on the surface of cells it causes agglutination and
potentially cell death.138
It was previously shown in a preliminary study that lectins can be used for the
visualziation of fingerprints.139 However, this potential, to the best of our knowledge, has not
been fully exploited by Forensic Scientists.
4.2: Development of Fingerprints with Fluorescently Labeled ConA
In order to test whether ConA is suitable for visualizing fingerprints, it was chemically
biotinylated and tested on marks deposited on nitrocellulose membranes. In addition to sweat
prints also blood marks were investigated (Figure 4.34). In both cases good ridge detail was
obtained, and it was decided to further pursue this approach and produce fluorescently labeled
ConA using NHS-fluorescein. As seen in Figure 4.35, the conjugate was useful for visualization
of marks deposited by three different (two weak and one strong) donors on PVDF membranes.
Also marks on aluminum foil could successfully be developed as seen in Figure 4.36 for a five
day aged mark as well as a two week aged mark deposited by a weak donor.
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Figure 4.34: Visualization of Sweat (left) and Blood (right) Marks Deposited on Nitrocellulose Membranes using
Biotinylated ConA and Streptavidin-HRP. The HRP-substrate was TMB for the sweat mark, but 4-Chloro-1-napthol
for the blood mark as TMB reacts with blood.

Figure 4.35: Fresh fingermarks on PVDF developed with Fluorescein-Labeled Con A. Right: strong donor. Middle
and left: weak donors. Fluorescence was excited filter using the Polilight PL550XL forensic light source at 430 nm
and emission was recorded using a 530 nm. Images provided by Dr. Xanthe Spindler.
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Figure 4.36: Aged Marks Deposited by a Weak Donor on Aluminum Foil that was Visualized with FluoresceinLabeled ConA. Left: five days aged. Right: two weeks aged. Fluorescence was excited filter using the Polilight
PL550XL forensic light source at 430 nm and emission was recorded using a 530 nm. Images provided by Dr.
Xanthe Spindler.
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CHAPTER V
CONCLUSIONS
Part I
The ability to generate immunoaffinity capture reagents utilizing molecular biological
techniques offers a variety of advantages compared to traditional, animal-based production
methods. Specificity and affinity of such antibodies or antigen-binding fragments, which can be
expressed in large quantities and at comparatively low cost in, e.g., bacterial cell cultures, may
be modulated using mutagenesis techniques based on rational design or library approaches. In
addition, unnatural amino acids with unique reactive chemical properties or amino acid
sequences that serve as recognition sites for other capture regents or enzymes capable of adding
labels can be incorporated at basically any position in the protein.75-76, 140-141 Here, an antimethotrexate VHH was modified at its C-terminus to achieve site-directed immobilization onto
chromatographic support materials via a tetra-lysine tail or an enzymatically biotinylated
AviTag, and the resulting columns were compared with one that was produced using random
amine-coupling. While both site-directed approaches yielded a higher number of active binding
sites, the effect was particularly pronounced for the column produced using the AviTag/BirA
approach. It was shown that site-directed biotinylation is necessary to achieve the increase in
binding capacity, as demonstrated by the decrease in available binding sites obtained with a
randomly biotinylated antibody. To the best of our knowledge, this constitutes the first reported
use of AviTag/BirA-based site-directed biotinylation for chromatographic separations. As the
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AviTag can readily be incorporated into basically any genetically engineered protein, this
method should have wide general utility and be of great value for other affinity chromatography
systems. The increased number of binding sites that can result from the oriented immobilization
of capture reagents should be of particular use for preparative applications.
Part II
Fingerprints are unique to each individual, and do not change over time.28 Therefore, they
are considered one of the strongest pieces of physical evidence in criminal investigations. 29 The
ability to tailor-make antibodies against basically any kind of molecule, also those contained in
fingermarks, makes immunolabeling an attractive method for the visualization of
fingermarks.27,27, 35-36, 98 Here, classically raised antibodies as well as recombinantly expressed
VHH antibodies and a carbohydrate-binding lectin were produced and evaluated for their ability
to visualize fingermarks, respectively.
Cholic acid, pregnenolone, and hemin were utilized as haptens for the production of
polyclonal antibodies in rabbits. Following purification, binding activity was tested and the
utility of the antibodies for visualization of latent fingermarks on a variety of substrates
confirmed. Despite the structural and stereochemical differences between cholic acid and
cholesterol, which is found in fingerprints in relatively large amounts, the anti-cholic acid
antibodies allowed visualization of marks deposited on membranes. However, the antibodies to
pregnenolone, which – with exception of the alkyl side chain - is structurally identical to
cholesterol, are expected to find wider applicability for fingermark visualization. The
competitive tests performed with the anti-pregnenolone antibodies using BSA-pregnenolone as
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inhibitor indicate that the binding to components in the mark are largely specific. However, more
competitive tests, e.g., utilizing preincubation of these and other antibodies with inhibitors before
application onto a mark, will be required to determine the extent of specific versus potential nonspecific interactions. The anti-hemin antibodies produced here could successfully be used for
visualization of fingermark ridges of both sweat and blood on two different surfaces. However, a
potential disadvantage of these and any other polyclonal antibodies is their possible binding
variability, as well as their limited availability due to the limited lifespan of the animal.
Since the molecular biological production of antibodies offers a possible solution to these
types of limitations, the utility of single domain camelid antibodies for the development of latent
fingermarks was investigated. Genetic engineering techniques were employed to produce a
variety of VHHs and fluorescent fusion proteins thereof. The utility of antibodies directed
against caffeine, RNaseA, and folate, for the visualization of marks deposited on nitrocellulose
membranes was demonstrated, and the fluorescent variants containing GFP, TSapphire,
mAmetrine, or mRuby could be employed for detecting marks on a variety of surfaces. To the
best of our knowledge, this is the first use of single domain antibodies and fluorescent proteins
for fingermark visualization. It was observed, however, that there were significant differences
with regard to the extent of non-specific interaction between these fluorescent proteins and
fingermark deposits. While no nonspecific interaction was observed with GFP, and only minor
nonspecific interactions with the GFP-variants mAmetrine and TSapphire, significant
nonspecific interaction occurred with mRuby. The time-dependent results obtained with the anticaffeine antibody indicate specific interactions with the fingermarks. Though the consumption of
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caffeine and theobromine is quite widespread across the population116 it appears that the ability
to develop marks from an individual donor is indeed influenced by this person’s dietary habits.
Additional investigations will be necessary to unambiguously demonstrate how factors such as
the quantity of caffeine-containing drinks or foods consumed, or the time passed since
consumption, affect the quality of visualized marks. The anti-methotrexate VHH, both as
biotinylated reagent and as a fluorescent fusion protein, could also be used to detect latent
fingermarks on membranes and glass, respectively. However, the anti-methotrexate VHH has
only a millimolar affinity for folate, the most likely target in fingermarks, which should limit its
utility. Optimizing this VHH so that it displays a higher affinity for folate might make this a
more widely usable reagent. It appears that due to the omnipresence of RNases, especially on
fingertips, the anti-RNaseA antibody should be a particularly promising reagent. However, the
variant used in this study does not express in a soluble form, which makes it difficult to produce
and purify larger quantities. Therefore, optimization of the expression system and additional
testing of the anti-RNaseA fluorescent fusion proteins should be performed to assess the full
potential of these reagents. Anyway, this study clearly shows that recombinantly expressed
single-domain antibodies and their fluorescent fusion proteins are a viable option for latent
fingermark development.
Widespread use of biorecognition-based reagents by practitioners will require the ability
to produce large quantities of such reagents at low cost. While the molecular biological
production of antibodies is a step in the right direction, the use of readily available, cheap
receptor proteins such as Concanavalin A is especially intriguing. Here, Concanavalin A was
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biotinylated and successfully used for visualization of both sweat and blood marks on
nitrocellulose membranes. In addition, fluorescently labeled Concanavalin A could be used for
detection of fingermarks on PVDF and aluminum foil. It is surprising that despite the fact that
the use of lectins for fingermark detection has been previously reported, they have not been
exploited in Forensic Science. However, the excellent results obtained in this study clearly
demonstrate the great promise of lectin-based capture reagents for this type of application. Since
they can bind to a variety of saccharides known to be present on a variety of cell surfaces137-138,
they should have wide applicability.
While the focus of the second part of this dissertation was to produce affinity capture
reagents directed against components contained in fingermarks and test their overall utility for
their fingermark visualization, further investigations will be necessary to assess the full potential
of these reagents, e.g., for routine and in-the-field applications.
A summary of the advantages and disadvantages of each of the bioaffinity reagents
investigated here is presented in Table 5.1.
Table 5.1: Summary of Bioaffinity Reagents Utilized for Latent Fingermark Detection.

Type

Name

Anti-Cholic Acid

Advantages
 Cholic acid is
structurally similar to
cholesterol.
 Good immune
response and antibody
production with good
titer.
 Binding activity
tested in noncompetitive tests.

Disadvantages
 Difference in
steroid structure
(change from 5α to
5β) may impair
recognition of
cholesterol and
cholesterol esters,
which account to
~5% w/v of sebum.
 Polyclonal
production: Limited
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 Development of
marks demonstrated
on membrane.
Polyclonal
Antibodies

Anti-Pregnenolone

Anti-Hemin

 Great structural and
stereochemical
similarity to
cholesterol (5).
 Good immune
response and antibody
production with good
titer.
 Binding activity
tested in noncompetitive tests.
 Development of
marks from both
strong and weak
donors on various
substrates was
demonstrated.
 Competitive tests with
marks in the presence
of BSA-pregnenolone
indicate a specific
interaction between
antibody and targets
in the mark.
 Heme is an important
co-factor of many
proteins.
 Good immune
response and antibody
production with good
titer.
 Binding activity
tested in noncompetitive tests.

lifetime of animal;
potentially
variability of
antibodies
produced.
 Requires chemical
labeling.
 Polyclonal
production: Limited
lifetime of animal;
potentially
variability of
antibodies
produced.
 Requires chemical
labeling.

 Polyclonal
production: Limited
lifetime of animal;
potentially
variability of
antibodies
produced.
 Requires chemical
labeling.
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Anti-Caffeine
VHH

Anti-RNaseA

 Development of both
sweat marks on
membranes and blood
marks on aluminum
foil.
 Low nanomolar
affinity for caffeine
and high nanomolar
affinity for the
metabolites
theobromine and
paraxanthine.
 Wide consumption of
methylxanthines
throughout the
population.
 Recombinantly
expressed and can be
genetically
engineered, e.g. with
fluorescent proteins.
 Development of
fingermarks from
strong and weak
donors with both
biotinylated and
fluorescent proteins
demonstrated.
 Time-dependent
studies show that
ridge detail correlates
to half-life of caffeine
following
consumption.
 Competitive tests
indicated a specific
interaction between
antibody and
fingermark.
 RNases are known
components of
fingerprints.

 Presence of target
(caffeine and
metabolites) in
mark dependent on
dietary habits, and
factors such as the
amount consumed
and time since
consumption.

 Insoluble protein
makes it difficult to
obtain the
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 VHH has low
nanomolar affinity for
RNaseA, which is
structurally related to
the two RNases
(RNase 7 and 10)
present in fingerprint
secretions.
 Recombinantly
expressed and can be
genetically
engineered, e.g., with
fluorescent proteins.
 Development of
fingermarks with both
biotinylated and
fluorescent proteins
demonstrated.
Anti-Methotrexate

Lectins

Concanavalin A

 Binds to folate and
structurally similar
derivatives, such as
methotrexate and
aminopterin.
 Recombinantly
expressed and can be
genetically
engineered, e.g., with
fluorescent proteins.
 Strong ridge pattern
observed in both
fluorescent
microscopy and
membrane tests.
 Proven cell/red blood
cell agglutinator.
 Cheap and easy to
isolate.
 Shown to bind to a
wide variety of
glucose/mannose

fluorescent protein
in high yields.

 Mark development
was inconsistent,
which may be due
to the weak
(millimolar) affinity
for folate.

 Requires chemical
labeling.
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containing
saccharides.
 Commercially
available.
 Development of both
sweat and blood
marks from weak and
strong donors
demonstrated on a
variety of substrates.
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APPENDIX
PROTEIN AND PLASMID INFORMATION
Protein Name
aRNAseA WT
aRNASeA-Tsapphire
aRNASeA-mRuby
aRNAseA-mAmetrine
aRNASeA GFP

Extinction Coefficition
(M-1 cm -1)
MW (Da)
29,000
16,195
50,890
47,120
55,000
45,325
55,000
46,899
51,890
43,035

aMTX-WT-GFP

57,425

43,787

aCaff-wt-m
Acaff-wt-m-gfp
Acaff-wt-m-mAmetrine
Acaff-wt-m-mRuby
Acaff-wt-m-Tsapphire

30035
52925
59000
59000
55000

13155
39995
46961
45444
46441

mRuby
mAmetrine
Tsapphire
GFP

26000
26000
21890
22890

29130
30704
30841
26840
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Anti-RNaseA mAmetrine- pET 21a+
1).Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCAASGYAY
TYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRFTISRDKGKNTVYLQMDSL
KPEDTATYYCAAGGYELRDRTYGQWGQGTQVTVSSGGMGGSHHHHHHGMASMTGG
QQMGRDLYDDDDKDPSSSMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATY
GKLTLKFICTTGKLPVPWPTLVTTFSYGVMVFARYPDHMKQHDFFKSAMPEGYVQERTI
FFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYIMADKQ
KNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSIQSKLSKDPNEKRD
HMVLLEFVTAAGITLGMDELYK
2). DNA sequence from Start to Stop
atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcgcagcaagcggttacgcatacacctacatctacat
gggttggttccgtcaagcaccaggtaaagaacgtgaaggtgtagcagcaatggacagcggtggtggtggtactctgtacgcagacagcgt
aaaaggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcaaccta
ctactgcgcagcaggtggttacgaactgcgtgaccgtacctacggtcaatggggtcaaggcacccaagtaaccgtaagcagcgggggga
tggggggttctcatcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgataag
gatccgagctcgagcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacg
gccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctg
cccgtgccctggcccaccctcgtgaccaccttctcctacggcgtgatggtgttcgcccgctaccccgaccacatgaagcagcacgacttctt
caagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagt
tcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagta
caacttcaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggccaacttcaagatccgccacaacatcgagga
cggcggcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagc
atccagtccaagctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcact
ctgggcatggacgagctgtacaagtaa
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3). Full Plasmid Map
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Anti-RNaseA mRuby- pET 21a+
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCAASGYAY
TYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRFTISRDKGKNTVYLQMDSL
KPEDTATYYCAAGGYAYTYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRF
TISRDKGKNTVYLQMDSLKPEDTATYYCAAGGYELRDRTYGQWGQGTQVTVSSGGMA
SMTGGQQMGRDLYENLYFQGSSMNSLIKENMRMKVVLEGSVNGHQFKCTGEGEGNPY
MGTQTMRIKVIEGGPLPFAFDILATSFMYGSRTFIKYPKGIPDFFKQSFPEGFTWERVTRY
EDGGVITVMQDTSLEDGCLVYHAQVRGVNFPSNGAVMQKKTKGWEPNTEMMYPADG
GLRGYTHMALKVDGGGHLSCSFVTTYRSKKTVGNIKMPGIHAVDHRLERLEESDNEMF
VVQREHAVAKFAGLGGG2). DNA Sequence From Start to Stop
atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcgcagcaagcggttacgcatacacctacatctacat
gggttggttccgtcaagcaccaggtaaagaacgtgaaggtgtagcagcaatggacagcggtggtggtggtactctgtacgcagacagcgt
aaaaggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcaaccta
ctactgcgcagcaggtggttacgcatacacctacatctacatgggttggttccgtcaagcaccaggtaaagaacgtgaaggtgtagcagca
atggacagcggtggtggtggtactctgtacgcagacagcgtaaaaggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacc
tgcagatggacagcctgaaaccagaagacaccgcaacctactactgcgcagcaggtggttacgaactgcgtgaccgtacctacggtcaat
ggggtcaaggcacccaagtaaccgtaagcagcggggggatggctagcatgactggtggacagcaaatgggtcgggatctgtacgagaa
cctgtacttccagggctcgagcatgaacagcctgatcaaagaaaacatgcggatgaaggtggtgctggaaggcagcgtgaacggccacc
agttcaagtgcaccggcgagggcgagggcaacccctacatgggcacccagaccatgcggatcaaagtgatcgagggcggacctctgcc
cttcgccttcgacatcctggccacatccttcatgtacggcagccggaccttcatcaagtaccccaagggcatccccgatttcttcaagcagag
cttccccgagggcttcacctgggagagagtgaccagatacgaggacggcggcgtgatcaccgtgatgcaggacaccagcctggaagat
ggctgcctggtgtaccatgcccaggtcaggggcgtgaattttcccagcaacggcgccgtgatgcagaagaaaaccaagggctgggagcc
caacaccgagatgatgtaccccgctgacggcggactgagaggctacacccacatggccctgaaggtggacggcggagggcacctgag
ctgcagcttcgtgaccacctaccgatccaagaaaaccgtgggcaacatcaagatgcccggcatccacgccgtggaccaccggctggaaa
ggctggaagagtccgacaacgagatgttcgtggtgcagcgggagcacgccgtggccaagttcgccggcctgggcggagggtaa
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3. Plasmid Map

141

Anti-RNaseA TSapphire pET21a+
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCAASGYAY
TYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRFTISRDKGKNTVYLQMDSL
KPEDTATYYCAAGGYELRDRTYGQWGQGTQVTVSSGGMGGSHHHHHHGMASMTGG
QQMGRDLYDDDDKDPSSSMVSKGDELFTGVVPILVELDGDVNGHKFSVSGEGEGDAT
YGKLTLKFICTTGKLPVPWPTLVTTFSYGVMVFARYPDHMKQHDFFKSAMPEGYVQER
TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYIMAD
KQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSIQSKLSKDPNEK
RDHMVLLEFVTAAGITLGMDELYK2). DNA Sequence From Start to Stop
atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcgcagcaagcggttacgcatacacctacatctac
atgggttggttccgtcaagcaccaggtaaagaacgtgaaggtgtagcagcaatggacagcggtggtggtggtactctgtacgcagacagc
gtaaaaggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcaacc
tactactgcgcagcaggtggttacgaactgcgtgaccgtacctacggtcaatggggtcaaggcacccaagtaaccgtaagcagcggggg
gatggggggttctcatcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgata
aggatccgagctcgagcatggtgagcaagggcgacgagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaa
cggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaag
ctgcccgtgccctggcccaccctcgtgaccaccttctcctacggcgtgatggtgttcgcccgctaccccgaccacatgaagcagcacgact
tcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtga
agttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctgga
gtacaacttcaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggccaacttcaagatccgccacaacatcga
ggacggcggcgtacagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctg
agcatccagtccaagctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactct
gggcatggacgagctgtacaagtaa
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3. Full Plasmid Map
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Anti-RNaseA GFP
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCAASGYAY
TYIYMGWFRQAPGKEREGVAAMDSGGGGTLYADSVKGRFTISRDKGKNTVYLQMDSL
KPEDTATYYCAAGGYELRDRTYGQWGQGTQVTVSSGGMSKGEELFTGVVPILVELDG
DVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGVQCFARYPDHM
KQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNIL
GHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLP
DNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK2). DNA Sequence from Start to Stop
atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcgcagcaagcggttacgcatacacctacatctacat
gggttggttccgtcaagcaccaggtaaagaacgtgaaggtgtagcagcaatggacagcggtggtggtggtactctgtacgcagacagcgt
aaaaggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcaaccta
ctactgcgcagcaggtggttacgaactgcgtgaccgtacctacggtcaatggggtcaaggcacccaagtaaccgtaagcagcgggggga
tgagtaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtcagtggagagg
gtgaaggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatggccaacacttgtcactactttcg
gttatggtgttcaatgctttgcgagatacccagatcatatgaaacagcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaag
aactatatttttcaaagatgacgggaactacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggt
attgattttaaagaagatggaaacattcttggacacaaattggaatacaactataactcacacaatgtatacatcatggcagacaaacaaaaga
atggaatcaaagttaacttcaaaattagacacaacattgaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcg
atggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatcccaacgaaaagagagaccacatggtccttct
tgagtttgtaacagctgctgggattacacatggcatggatgaactatacaaataatag
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3). Full Plasmid Map
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Anti-Caffeine mAmetrine
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCTASGRTGT
IYSMAWFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKP
EDTAVYYCTATRAYSVGYDYWGQGTQVTVSSGGMGGSHHHHHHGMASMTGGQQMG
RDLYDDDDKDPSSSMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT
LKFICTTGKLPVPWPTLVTTFSYGVMVFARYPDHMKQHDFFKSAMPEGYVQERTIFFKD
DGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYIMADKQKNGI
KANFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSIQSKLSKDPNEKRDHMVL
LEFVTAAGITLGMDELYK2). DNA Sequence from Start to Stop
atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcaccgcttccggtcgtaccggtaccatctactccatg
gcttggttccgtcaagcaccaggtaaagaacgtgaattcctggctaccgttggttggtcctccggtatcacctactacatggacagcgtaaaa
ggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcagtttactact
gcaccgctacccgtgcttactccgttggttacgactactggggtcaaggcacccaagtaaccgtaagcagcggggggatggggggttctc
atcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgataaggatccgagctcg
agcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttca
gcgtttccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctgg
cccaccctcgtgaccaccttctcctacggcgtgatggtgttcgcccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccat
gcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgac
accctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaacttcaacag
ccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggccaacttcaagatccgccacaacatcgaggacggcggcgtgc
agctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcatccagtccaag
ctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctgggcatggacgagct
gtacaagtaa
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3). Full plasmid Map
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Anti-Caffeine TSapphire
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCTASGRTGTIYSMA
WFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKPEDTAVYYCTA
TRAYSVGYDYWGQGTQVTVSSGGMGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSSM
VSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFS
YGVMVFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGI
DFKEDGNILGHKLEYNFNSHNVYIMADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGP
VLLPDNHYLSIQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK2). DNA Sequence from Start to Stop

atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaac
tggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcaccgcttccggtcgtaccggtaccatctactccatg
gcttggttccgtcaagcaccaggtaaagaacgtgaattcctggctaccgttggttggtcctccggtatcacctactacatggacagcgtaaaa
ggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcagtttactact
gcaccgctacccgtgcttactccgttggttacgactactggggtcaaggcacccaagtaaccgtaagcagcggggggatggggggttctc
atcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgataaggatccgagctcg
agcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttca
gcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctg
gcccaccctcgtgaccaccttctcctacggcgtgatggtgttcgcccgctaccccgaccacatgaagcagcacgacttcttcaagtccgcca
tgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcga
caccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaacttcaaca
gccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggccaacttcaagatccgccacaacatcgaggacggcggcgtg
cagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcatccagtccaa
gctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctgggcatggacgagc
tgtacaagtaa
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3). Full Plasmid Map
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Anti-Caffeine mRuby
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCTASGRTGT
IYSMAWFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKP
EDTAVYYCTATRAYSVGYDYWGQGTQVTVSSGGMASMTGGQQMGRDLYENLYFQGS
SMNSLIKENMRMKVVLEGSVNGHQFKCTGEGEGNPYMGTQTMRIKVIEGGPLPFAFDIL
ATFFMYGSRTFIKYPKGIPDFFKQSFPEGFTWERVTRYEDGGVITVMQDTSLEDGCLVY
HAQVRGVNFPSNGAVMQKKTKGWEPNTEMMYPADGGLRGYTHMALKVDGGGHLSC
SFVTTYRSKKTVGNIKMPGIHAVDHRLERLEESDNEMFVVQREHAVAKFAGLGGG2). Full DNA Sequence from Start to Stop
Atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaa
ctggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcaccgcttccggtcgtaccggtaccatctactccat
ggcttggttccgtcaagcaccaggtaaagaacgtgaattcctggctaccgttggttggtcctccggtatcacctactacatggacagcgtaaa
aggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcagtttactac
tgcaccgctacccgtgcttactccgttggttacgactactggggtcaaggcacccaagtaaccgtaagcagcggggggatggctagcatga
ctggtggacagcaaatgggtcgggatctgtacgagaacctgtacttccagggctcgagcatgaacagcctgatcaaagaaaacatgcgga
tgaaggtggtgctggaaggcagcgtgaacggccaccagttcaagtgcaccggcgagggcgagggcaacccctacatgggcacccaga
ccatgcggatcaaagtgatcgagggcggacctctgcccttcgccttcgacatcctggccacattcttcatgtacggcagccggaccttcatc
aagtaccccaagggcatccccgatttcttcaagcagagcttccccgagggcttcacctgggagagagtgaccagatacgaggacggcgg
cgtgatcaccgtgatgcaggacaccagcctggaagatggctgcctggtgtaccatgcccaggtcaggggcgtgaattttcccagcaacgg
cgccgtgatgcagaagaaaaccaagggctgggagcccaacaccgagatgatgtaccccgctgacggcggactgagaggctacaccca
catggccctgaaggtggacggcggagggcacctgagctgcagcttcgtgaccacctaccgatccaagaaaaccgtgggcaacatcaag
atgcccggcatccacgccgtggaccaccggctggaaaggctggaagagtccgacaacgagatgttcgtggtgcagcgggagcacgcc
gtggccaagttcgccggcctgggcggagggtaa
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3). Full Plasmid Map
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Anti-Caffeine GFP
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCTASGRTGT
IYSMAWFRQAPGKEREFLATVGWSSGITYYMDSVKGRFTISRDKGKNTVYLQMDSLKP
EDTAVYYCTATRAYSVGYDYWGQGTQVTVSSGGMSKGEELFTGVVPILVELDGDVNG
HKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGVQCFARYPDHMKQHD
FFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLE
YNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHY
LSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK-2). Full DNA Sequence from Start to Stop
Atgaaacatcatcatcatcatcacagcagcgactacaaagacgacgatgacaaaggtgaaaacctgtacttccagggatcccaagtacaa
ctggtagaaagcggtggtggtctggtacaagcaggtggtagcctgcgtctgagctgcaccgcttccggtcgtaccggtaccatctactccat
ggcttggttccgtcaagcaccaggtaaagaacgtgaattcctggctaccgttggttggtcctccggtatcacctactacatggacagcgtaaa
aggtcgtttcaccatcagccgtgacaaaggtaaaaacaccgtatacctgcagatggacagcctgaaaccagaagacaccgcagtttactac
tgcaccgctacccgtgcttactccgttggttacgactactggggtcaaggcacccaagtaaccgtaagcagcggggggatgagtaaagga
gaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtcagtggagagggtgaaggtgat
gcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacctgttccatggccaacacttgtcactactttcggttatggtgttc
aatgctttgcgagatacccagatcatatgaaacagcatgactttttcaagagtgccatgcccgaaggttatgtacaggaaagaactatatttttc
aaagatgacgggaactacaagacacgtgctgaagtcaagtttgaaggtgatacccttgttaatagaatcgagttaaaaggtattgattttaaag
aagatggaaacattcttggacacaaattggaatacaactataactcacacaatgtatacatcatggcagacaaacaaaagaatggaatcaaa
gttaacttcaaaattagacacaacattgaagatggaagcgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtcc
ttttaccagacaaccattacctgtccacacaatctgccctttcgaaagatcccaacgaaaagagagaccacatggtccttcttgagtttgtaaca
gctgctgggattacacatggcatggatgaactatacaaataatag
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3). Full Plasmid Map

Anti-Methotrexate-WT-GFP
1). Amino Acid Sequence
MKHHHHHHSSDYKDDDDKGENLYFQGSQVQLVESGGGLVQAGGSLRLSCAASRRSSR
SWAMAWFRQAPGKEREFVAKISGDGRLTTYGDSVKGRFTISRDNAEYLVYLQMDSLKP
EDTAVYYCAADDNYVTASWRSGPDYWGQGTQVTVSSGGMSKGEELFTGVVPILVELD
GDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGVQCFARYPDH
MKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNI
LGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVL
LPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDELYK-
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2). DNA Sequence
ATGAAACATCATCATCATCATCACAGCAGCGACTACAAAGACGACGATGACAAAGG
TGAAAACCTGTACTTCCAGGGATCCCAAGTACAACTGGTAGAAAGCGGTGGTGGTC
TGGTACAAGCAGGTGGTAGCCTGCGTCTGAGCTGCGCAGCATCCCGTCGTTCCTCCC
GTTCCTGGGCTATGGCTTGGTTCCGTCAAGCACCAGGTAAAGAACGTGAATTTGTGG
CGAAAATTAGCGGCGATGGCCGTCTGACCACCTATGGAGACAGCGTAAAAGGTCGT
TTCACCATCAGCCGTGACAACGCGGAATATCTGGTGTATCTGCAGATGGACAGCCTG
AAACCAGAAGACACCGCAGTTTACTACTGCGCTGCTGATGATAACTATGTGACCGCG
AGCTGGCGTAGCGGCCCGGATTATTGGGGCCAGGGCACCCAAGTAACCGTAAGCAG
CGGTGGTATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGA
ATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTG
ATGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTG
TTCCATGGCCAACACTTGTCACTACTTTCGGTTATGGTGTTCAATGCTTTGCGAGATA
CCCAGATCATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGT
ACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAG
TCAAGTTTGAA.GGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTA
AAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAAT
GTATACATCATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAG
ACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAA.TACTC
CAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATCTG
CCCTTTCGAAAGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAA
CAGCTGCTGGGATTACACATGGCATGGATGAACTATACAAATAA
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3). Full Plasmid Map

GFP (Addgene plasmid #14076)
1). Amino Acid Sequence
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT
LVTTFGYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGD
TLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQ
LADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITHGMDE
LYK-
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2). Full DNA Sequence from Start to Stop
ATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGAT
GGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAAC
ATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCATG
GCCAACACTTGTCACTACTTTCGGTTATGGTGTTCAATGCTTTGCGAGATACCCAGAT
CATATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAA
AGAACTATATTTTTCAAAGATGACGGGAACTACAAGACACGTGCTGAAGTCAAGTTT
GAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAGGTATTGATTTTAAAGAAGAT
GGAAACATTCTTGGACACAAATTGGAATACAACTATAACTCACACAATGTATACATC
ATGGCAGACAAACAAAAGAATGGAATCAAAGTTAACTTCAAAATTAGACACAACAT
TGAAGATGGAAGCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCG
ATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCCACACAATCTGCCCTTTCGAA
AGATCCCAACGAAAAGAGAGACCACATGGTCCTTCTTGAGTTTGTAACAGCTGCTGG
GATTACACATGGCATGGATGAACTATACAAATAAATGTCCAGACCTGCAGGCATGC
AAGCTTGATA
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3). Partial Plasmid Map

mRuby (Addgene Plasmid #54763)
1). Full Amino Acid Sequence
MRGSHHHHHHGMASMTGGQQMGRDLYENLYLQGSSMNSLIKENMRMKVVLEGSVN
GHQFKCTGEGEGNPYMGTQTMRIKVIEGGPLPFAFDILATSFMYGSRTFIKYPKGIPDFF
KQSFPEGFTWERVTRYEDGGVITVMQDTSLEDGCLVYHAQVRGVNFPSNGAVMQKKT
KGWEPNTEMMYPADGGLRGYTHMALKVDGGGHLSCSFVTTYRSKKTVGNIKMPGIHA
VDHRLERLEESDNEMFVVQREHAVAKFAGLGGG-
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2). DNA Sequence from Start to Stop
atgcggggttctcatcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgagaacctgtacttg
cagggctcgagcatgaacagcctgatcaaagaaaacatgcggatgaaggtggtgctggaaggcagcgtgaacggccaccagttcaagt
gcaccggcgagggcgagggcaacccctacatgggcacccagaccatgcggatcaaagtgatcgagggcggacctctgcccttcgcctt
cgacatcctggccacatccttcatgtacggcagccggaccttcatcaagtaccccaagggcatccccgatttcttcaagcagagcttccccg
agggcttcacctgggagagagtgaccagatacgaggacggcggcgtgatcaccgtgatgcaggacaccagcctggaagatggctgcct
ggtgtaccatgcccaggtcaggggcgtgaattttcccagcaacggcgccgtgatgcagaagaaaaccaagggctgggagcccaacacc
gagatgatgtaccccgctgacggcggactgagaggctacacccacatggccctgaaggtggacggcggagggcacctgagctgcagct
tcgtgaccacctaccgatccaagaaaaccgtgggcaacatcaagatgcccggcatccacgccgtggaccaccggctggaaaggctgga
agagtccgacaacgagatgttcgtggtgcagcgggagcacgccgtggccaagttcgccggcctgggcggagggtaa
3). Full Plasmid Map
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mAmetrine (Addgene plasmid #18084)
1). Full Amino Acid Sequence
MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSSMVSKGEELFTGVVPILVELD
GDVNGHRFSVRGEGEGDATNGKLTLKFICTSGELPVPWPTLVTTLSYGVQCFARYPDH
MKQHDFFKSAMPEGYVQERTISFKDDGSYRTRAEVKFEGDTLVNRIELKGIDFKEDGNI
LGHKLEYNMNAWDAYITADKQKNGIKANFKIEHNVKDGGVQLADAYQQNTPIGDGSV
LLPDNHYLSFQSKLFKDPNEQRDHMVLLEFVTAAGITPGMDELYK2). DNA Sequence from Start to Stop
Atggggggttctcatcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgataa
ggatccgagctcgagcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaac
ggccacaggttcagcgtgcgcggcgagggcgagggcgatgccaccaacggcaagctgaccctgaagttcatctgcacctccggcgagc
tgcccgtgccctggcccaccctcgtgaccaccctgtcttacggcgtgcagtgcttcgcccgctaccccgaccacatgaagcagcacgactt
cttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatctccttcaaggacgacggcagctacaggacccgcgccgaggtga
agttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctgga
gtacaacatgaacgcgtgggacgcgtatatcacggccgacaagcagaagaacggcatcaaagcgaacttcaagatcgagcacaacgtca
aggacggcggcgtgcagctcgccgacgcgtaccagcagaacacccccatcggcgacggctccgtgctgctgcctgacaaccactacct
gagcttccagagcaagctgttcaaagaccccaacgagcagcgcgatcacatggtcctgctggagttcgttaccgccgccgggataactcc
cggcatggacgagctgtacaagtaa
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3). Full Plasmid Map
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TSapphire (Addgene Plasmid #18084)
1). Full Amino Acid Sequence
MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSSMVSKGEELFTGVVPILVELD
GDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVMVFARYPDH
MKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNI
LGHKLEYNFNSHNVYIMADKQKNGIKANFKIRHNIEDGGVQLADHYQQNTPIGDGPVL
LPDNHYLSIQSKLSKDPNEKRDHMVLLEFVTAAGITLGMDELYK-

2). DNA Sequence from Start to Stop
atggggggttctcatcatcatcatcatcatggtatggctagcatgactggtggacagcaaatgggtcgggatctgtacgacgatgacgataa
ggatccgagctcgagcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaac
ggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagct
gcccgtgccctggcccaccctcgtgaccaccttctcctacggcgtgatggtgttcgcccgctaccccgaccacatgaagcagcacgacttc
ttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaa
gttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggag
tacaacttcaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggccaacttcaagatccgccacaacatcgag
gacggcggcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctga
gcatccagtccaagctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctg
ggcatggacgagctgtacaagaa
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3). Full Plasmid Map
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Molecular Chaperone Plasmid PBB550 containing DnaJ, DnaK, and GroELS (Addgene
plasmid # 27396)
1). Full Plasmid DNA Sequence
GACGTCTGTGTGGAATTGTGAGCGGATAACAAaTTCACACAGGGCCCTCGGACACCG
AGGAGAATGTCAAGAGGCGAACACACAACGTCTTGGAGCGCCAGAGGAGGAACGA
GCTAAAACGGAGCTTTTTTGCCCTGCGTGACCAGATCCCGGAGTTGGAAAACAATGA
AAAGGCCCCCAAGGTAGTTATCCTTAAAAAAGCCACAGCATACATCCTGTCCGTCCA
AGCAGAGGAGCAAAAGCTCATTTCTGAAGAGGACTTGTTGCGGAAACGACGAGAAC
AGTTGAAACACAAACTTGAACAGCTACGGAACTCTTGTGCGTAAGGAAAAGTAAGG
AAAACGATTCCTTCTAACAGAAATGTCCTGAGCAATCACCTATGAACTGTCGACTCG
ACAATTCGCGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGG
AAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT
TGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGA
TTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGC
CCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCT
GTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGA
CTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGC
AGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGC
ACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTA
TGCCAGCCAGCCAGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAG
CGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCCCAGTCGCGTACCGTC
TTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAATA
ACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGC
GGATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCT
TTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGT
TGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAG
ACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGTGCCAC
GCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTTTCCCGCGTTTTC
GCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACC
GGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTG
ACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCACCATTCGATGGT
GTCAACGTAAATGCATGCCGCTTCGCCTTCGCGCGCGAATTGTCGAGAAAATTTATC
AAAAAGAGTGTTGACTTGTGAGCGGATAACAATGATACTTAGATTCAATTGTGAGC
GGATAACAATTTCACACAGAATTCATAAAGAGGAGAAAGGATCCATGGGTAAAATA
ATTGGTATCGACCTGGGTACTACCAACTCTTGTGTAGCGATTATGGATGGCACCACT
CCTCGCGTGCTGGAGAACGCCGAAGGCGATCGCACCACGCCTTCTATCATTGCCTAT
ACCCAGGATGGTGAAACTCTAGTTGGTCAGCCGGCTAAACGTCAGGCAGTGACGAA
CCCGCAAAACACTCTGTTTGCGATTAAACGCCTGATTGGTCGCCGCTTCCAGGACGA
AGAAGTACAGCGTGATGTTTCCATCATGCCGTTCAAAATTATTGCTGCTGATAACGG
CGACGCATGGGTCGAAGTTAAAGGCCAGAAAATGGCACCGCCGCAGATTTCTGCTG
AAGTGCTGAAAAAAATGAAGAAAACCGCTGAAGATTACCTGGGTGAACCGGTAACT
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GAAGCTGTTATCACCGTACCGGCATACTTTAACGATGCTCAGCGTCAGGCAACCAAA
GACGCAGGCCGTATCGCTGGTCTGGAAGTAAAACGTATCATCAACGAACCGACCGC
AGCTGCGCTGGCTTACGGTCTGGACAAAGGCACTGGCAACCGTACTATCGCGGTTTA
TGACCTGGGTGGTGGTACTTTCGATATTTCTATTATCGAAATCGACGAAGTTGACGG
CGAAAAAACCTTCGAAGTTCTGGCAACCAACGGTGATACCCACCTGGGGGGTGAAG
ACTTCGACAGCCGTCTGATCAACTATCTGGTTGAAGAATTCAAGAAAGATCAGGGC
ATTGACCTGCGCAACGATCCGCTGGCAATGCAGCGCCTGAAAGAAGCGGCAGAAAA
AGCGAAAATCGAACTGTCTTCCGCTCAGCAGACCGACGTTAA
CCTGCCATACATCACTGCAGACGCGACCGGTCCGAAACACATGAACATCAAAGTGA
CTCGTGCGAAACTGGAAAGCCTGGTTGAAGATCTGGTAAACCGTTCCATTGAGCCGC
TGAAAGTTGCACTGCAGGACGCTGGCCTGTCCGTATCTGATATCGACGACGTTATCC
TCGTTGGTGGTCAGACTCGTATGCCAATGGTTCAGAAGAAAGTTGCTGAGTTCTTTG
GTAAAGAGCCGCGTAAAGACGTTAACCCGGACGAAGCTGTAGCAATCGGTGCTGCT
GTTCAGGGTGGTGTTCTGACTGGTGACGTAAAAGACGTACTGCTGCTGGACGTTACC
CCGCTGTCTCTGGGTATCGAAACCATGGGCGGTGTGATGACGACGCTGATCGCGAA
AAACACCACTATCCCGACCAAGCACAGCCAGGTGTTCTCTACCGCTGAAGACAACC
AGTCTGCGGTAACCATCCATGTGCTGCAGGGTGAACGTAAACGTGCGGCTGATAAC
AAATCTCTGGGTCAGTTCAACCTAGATGGTATCAACCCGGCACCGCGCGGCATGCCG
CAGATCGAAGTTACCTTCGATATCGATGCTGACGGTATCCTGCACGTTTCCGCGAAA
GATAAAAACAGCGGTAAAGAGCAGAAGATCACCATCAAGGCTTCTTCTGGTCTGAA
CGAAGATGAAATCCAGAAAATGGTACGCGACGCAGAAGCTAACGCCGAAGCTGAC
CGTAAGTTTGAAGAGCTGGTACAGACTCGCAACCAGGGCGACCATCTGCTGCACAG
CACCCGTAAGCAGGTTGAAGAAGCAGGCGACAAACTGCCGGCTGACGACAAAACTG
CTATCGAGTCTGCGCTGACTGCACTGGAAACTGCTCTGAAAGGTGAAGACAAAGCC
GCTATCGAAGCGAAAATGCAGGAACTGGCACAGGTTTCCCAGAAACTGATGGAAAT
CGCCCAGCAGCAACATGCCCAGCAGCAGACTGCCGGTGCTGATGCTTCTGCAAACA
ACGCGAAAGATGACGATGTTGTCGACGCTGAATTTGAAGAAGTCAAAGACAAAAAA
TAAtcgccctataaacgggtaattatactgacacgggcgaaggggaatttcctctccgcccgtgcattcatctaggggcaatttaaaaaag
ATGGCTAAGCAAGATTATTACGAGATTTTAGGCGTTTCCAAAACAGCGGAAGAGCG
TGAAATCAGAAAGGCCTACAAACGCCTGGCCATGAAATACCACCCGGACCGTAACC
AGGGTGACAAAGAGGCCGAGGCGAAATTTAAAGAGATCAAGGAAGCTTATGAAGTT
CTGACCGACTCGCAAAAACGTGCGGCATACGATCAGTATGGTCATGCTGCGTTTGAG
CAAGGTGGCATGGGCGGCGGCGGTTTTGGCGGCGGCGCAGACTTCAGCGATATTTTT
GGTGACGTTTTCGGCGATATTTTTGGCGGCGGACGTGGTCGTCAACGTGCGGCGCGC
GGTGCTGATTTACGCTATAACATGGAGCTCACCCTCGAAGAAGCTGTACGTGGCGTG
ACCAAAGAGATCCGCATTCCGACTCTGGAAGAGTGTGACGTTTGCCACGGTAGCGG
TGCAAAACCAGGTACACAGCCGCAGACTTGTCCGACCTGTCATGGTTCTGGTCAGGT
GCAGATGCGCCAGGGATTCTTCGCTGTACAGCAGACCTGTCCACACTGTCAGGGCCG
CGGTACGCTGATCAAAGATCCGTGCAACAAATGTCATGGTCATGGTCGTGTTGAGCG
CAGCAAAACGCTGTCCGTTAAAATCCCGGCAGGGGTGGACACTGGAGACCGCATCC
GTCTTGCGGGCGAAGGTGAAGCGGGCGAGCATGGCGCACCGGCAGGCGATCTGTAC
GTTCAGGTTCAGGTTAAACAGCACCCGATTTTCGAGCGTGAAGGCAACAACCTGTAT
TGCGAAGTCCCGATCAACTTCGCTATGGCGGCGCTGGGTGGCGAAATCGAAGTACC
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GACCCTTGATGGTCGCGTCAAACTGAAAGTGCCTGGCGAAACCCAGACCGGTAAGC
TATTCCGTATGCGCGGTAAAGGCGTCAAGTCTGTCCGCGGTGGCGCACAGGGTGATT
TGCTGTGCCGCGTTGTCGTCGAAACACCGGTAGGCCTGAACGAAAGGCAGAAACAG
CTGCTGCAAGAGCTGCAAGAAAGCTTCGGTGGCCCAACCGGCGAGCACAACAGCCC
GCGCTCAAAGAGCTTCTTTGATGGTGTGAAGAAGTTTTTTGACGACCTGACCCGCTA
AGATGTCGACCTGCAGCCAAGCTTAATTAGCTGATCTAGAGGCATCAAATAAAACG
AAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGC
TCTCCTGAGTAGGACAAATCCGCCGCCCTAGACCTAGTCGAGGCAACGCAATTAAT
GTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTA
TGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGAATTCATTAAAGAGGAG
AAATTAACCatgaatattcgtccattgcatgatcgcgtgatcgtcaagcgtaaagaagttgaaactaaatctgctggcggcatcgttct
gaccggctctgcagcggctaaatccacccgcggcgaagtgctggctgtcggcaatggccgtatccttgaaaatggcgaagtgaagccgct
ggatgtgaaagttggcgacatcgttattttcaacgatggctacggtgtgaaatctgagaagatcgacaatgaagaagtgttgatcatgtccga
aagcgacattctggcaattgttgaagcgtaatccgcgcacgacactgaacatacgaatttaaggaataaagataATGGCAGCTAA
AGACGTAAAATTCGGTAACGACGCTCGTGTGAAAATGCTGCGCGGCGTAAACGTAC
TGGCAGATGCAGTGAAAGTTACCCTCGGTCCAAAAGGCCGTAACGTAGTTCTGGAT
AAATCTTTCGGTGCACCGACCATCACCAAAGATGGTGTTTCCGTTGCTCGTGAAATC
GAACTGGAAGACAAGTTCGAAAATATGGGTGCGCAGATGGTGAAAGAAGTTGCCTC
TAAAGCAAACGACGCTGCAGGCGACGGTACCACCACTGCAACCGTACTGGCTCAGG
CTATCATCACTGAAGGTCTGAAAGCTGTTGCTGCGGGCATGAACCCGATGGACCTGA
AACGTGGTATCGACAAAGCGGTTACCGCTGCAGTTGAAGAACTGAAAGCGCTGTCC
GTACCATGCTCTGACTCTAAAGCGATTGCTCAGGTTGGTACCATCTCCGCTAACTCC
GACGAAACCGTAGGTAAACTGATCGCTGAAGCGATGGACAAAGTCGGTAAAGAAG
GCGTTATCACCGTTGAAGACGGTACCGGTCTGCAGGACGAACTGGACGTGGTTGAA
GGTATGCAGTTCGACCGTGGCTACCTGTCTCCTTACTTCATCAACAAGCCGGAAACT
GGCGCAGTAGAACTGGAAAGCCCGTTCATCCTGCTGGCTGACAAGAAAATCTCCAA
CATCCGCGAAATGCTGCCGGTTCTGGAAGCTGTTGCCAAAGCAGGCAAACCGCTGC
TGATCATCGCTGAAGATGTAGAAGGCGAAGCGCTGGCAACTctgGTTGTTAACACCAT
gCGTGGCATCGTGAAAGTCGCTGCGGTTAAAGCACCGGGCTTCGGCGATCGTCGTAA
AGCTATGCTGCAGGATATCGCAACCCTGACTGGCGGTACCGTGATCTCTGAAGAGAT
CGGTATGGAGCTGGAAAAAGCAACCCTGGAAGACCTGGGTCAGGCTAAACGTGTTG
TGATCAACAAAGACACCACCACTATCATCGATGGCGTGGGTGAAGAAGCTGCAATC
CAGGGCCGTGTTGCTCAGATCCGTCAGCAGATTGAAGAAGCAACTTCTGACTACGAC
CGTGAAAAACTGCAGGAACGCGTAGCGAAACTGGCAGGCGGCGTTGCAGTTATCAA
AGTGGGTGCTGCTACCGAAGTTGAAATGAAAGAGAAAAAAGCACGCGTTGAAGATG
CCCTGCACGCGACCCGTGCTGCGGTAGAAGAAGGCGTGGTTGCTGGTGGTGGTGTTG
CGCTGATCCGCGTAGCGTCTAAACTGGCTGACCTGCGTGGTCAGAACGAAGACCAG
AACGTGGGTATCAAAGTTGCACTGCGTGCAATGGAAGCTCCGCTGCGTCAGATCGTA
TTGAACTGCGGCGAAGAACCGTCTGTTGTTGCTAACACCGTTAAAGGCGGCGACGG
CAACTACGGTTACAACGCAGCAACCGAAGAATACGGCAACATGATCGACATGGGTA
TCCTGGATCCAACCAAAGTAACTCGTTCTGCTCTGCAGTACGCAGCTTCTGTGGCTG
GCCTGATGATCACCACCGAATGCATGGTTACCGACCTGCCGAAAAACGATGCAGCT
GACTTAGGCGCTGCTGGCGGTATGGGCGGCATGGGTGGCATGGGCGGCATGATGTA
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AGCTTAATTAGCTGAGCTTGGACTCCTGTTGATAGATCCAGTAATGACCTCAGAACT
CCATCTGGATTTGTTCAGAACGCTCGGTTGCCGCCGGGCGTTTTTTATTGGTGAGAAT
CCAAGCTAGAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCG
TTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGCCCTAG
ACCTAGGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGTCGTTCGACT
GCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCCAGGA
AGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCC
GCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCG
ACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCT
GTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATTC
CACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACG
AACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCA
ACCCGGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGA
GGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTG
GTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGCTCAGAGAA
CCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAGCAAGAGATTACGC
GCAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAGA
TTTCAGTGCAATTTATCTCTTCAAATGTAGCACCTGAAGTCAGCCCCATACGATATA
AGTTGTTACTAGTGCTTGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCG
TTCTGAACAAATCCAGATGGAGTTCTGAGGTCATTACTGGATCTATCAACAGGAGTC
CAAGCGAGCTCGATATCCGTCGGCTTGAACGAATTGTTAGACATTATTTGCCGACTA
CCTTGGTGATCTCGCCTTTCACGTAGTGGACAAATTCTTCCAACTGATCTGCGCGCG
AGGCCAAGCGATCTTCTTCTTGTCCAAGATAAGCCTGTCTAGCTTCAAGTATGACGG
GCTGATACTGGGCCGGCAGGCGCTCCATTGCCCAGTCGGCAGCGACATCCTTCGGCG
CGATTTTGCCGGTTACTGCGCTGTACCAAATGCGGGACAACGTAAGCACTACATTTC
GCTCATCGCCAGCCCAGTCGGGCGGCGAGTTCCATAGCGTTAAGGTTTCATTTAGCG
CCTCAAATAGATCCTGTTCAGGAACCGGATCAAAGAGTTCCTCCGCCGCTGGACCTA
CCAAGGCAACGCTATGTTCTCTTGCTTTTGTCAGCAAGATAGCCAGATCAATGTCGat
CGTGGCTGGCTCGAAGATACCTGCAAGAATGTCATTGCGCTGCCATTCTCCAAATTG
CAGTTCGCGCTTAGCTGGATAACGCCACGGAATGATGTCGTCGTGCACAACAATGGT
GACTTCTACAGCGCGGAGAATCTCGCTCTCTCCAGGGGAAGCCGAAGTTTCCAAAA
GGTCGTTGATCAAAGCTCGCCGCGTTGTTTCATCAAGCCTTACGGTCACCGTAACCA
GCAAATCAATATCACTGTGTGGCTTCAGGCCGCCATCCACTGCGGAGCCGTACAAAT
GTACGGCCAGCAACGTCGGTTCGAGATGGCGCTCGATGACGCCAACTACCTCTGAT
AGTTGAGTCGATACTTCGGCGATCACCGCTTCCCTCATGATGTTTAACTTTGTTTTAG
GGCGACTGCCCTGCTGCGTAACATCGTTGCTGCTCCATAACATCAAACATCGACCCA
CGGCGTAACGCGCTTGCTGCTTGGATGCCCGAGGCATAGACTGTACCCCAAAAAAA
CAGTCATAACAAGCCATGAAAACCGCCACTGCGCCGTTACCACCGCTGCGTTCGGTC
AAGGTTCTGGACCAGTTGCGTGAGCGCATACGCTACTTGCATTACAGCTTACGAACC
GAACAGGCTTATGTCCACTGGGTTCGTGCCTTCATCCGGATATC
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2). Full Plasmid Map

